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ABSTRACT 
The pituitary acts as a central mediator of the endocrine system, integrating both 
hypothalamic and peripheral signals to coordinate physiological functions through the 
release of hormones from distinct endocrine cell types within the gland. During 
development, the endocrine cell types are derived from a common pituitary progenitor 
cell. To maintain the correct number of each cell type, it is essential that the pituitary 
coordinate progenitor maintenance and proliferation with the differentiation of the 
hormone producing cells. Disruption of the developmental pathways that are necessary 
for pituitary cell fate determination can result in pituitary disorders such as 
hypopituitarism, which is associated with several detrimental health conditions including 
growth deficiencies, adrenal insufficiency, infertility, and hypothyroidism. To understand 
the etiology of pituitary disorders we must elucidate the factors and molecular pathways 
that regulate pituitary cell fate choice and lineage specification. Previous studies from 
our laboratory have demonstrated that the Notch signaling pathway is an important 
regulator of pituitary cell fate choice. Specifically, Notch signaling is necessary for 
pituitary progenitor maintenance and coordinates the balance of endocrine cell 
differentiation. However, the mechanism by which the Notch signaling pathway 
regulates cell fate choice in the pituitary remains unclear. To identify novel downstream 
targets of Notch signaling that mediate its effect on pituitary development, a 
transcriptomic analysis was performed comparing pituitaries from mice with a 
conditional loss of the Notch2 receptor to controls. From this analysis, we identified the 
novel Notch regulated genes, grainyhead-like 2 (Grhl2) and 11-beta hydroxysteroid 
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dehydrogenase type 1 (Hsd11b1) as potential downstream effectors of the Notch 
signaling pathway that may influence pituitary development.  
The Notch signaling pathway has been shown to regulate progenitor cell proliferation 
and self-renewal capacity in several tissues. Previous studies in the pituitary 
demonstrate that loss of Notch signaling results in decreased progenitor cell number 
and proliferation, as well as a misplacement of the progenitor cell niche. Therefore, 
Notch signaling is necessary for progenitor cell function and presumably helps to 
maintain the extra-cellular environment required for progenitor cell localization. In this 
work, we identify Grhl2 as a novel pituitary progenitor factor that is dependent on Notch 
signaling in the developing pituitary. GRHL2 is present in several epithelial tissues 
where it has been shown to regulate plasticity by promoting cellular proliferation, 
inhibiting differentiation and maintaining cellular adhesion. Based on the functions of 
GRHL2 in other tissues, we hypothesize that Notch regulation of GRHL2 is a potential 
mechanism by which the pathway influences progenitor cell maintenance. Our studies 
demonstrate GRHL2 is expressed in pituitary progenitor cells throughout pituitary gland 
development, with its most pronounced expression during early postnatal development. 
Utilizing Notch2 cKO mice and chemical Notch inhibitors, we are the first to demonstrate 
that Grhl2 is dynamically regulated by Notch signaling in the postnatal pituitary. We 
observe that loss of Notch signaling results in a decrease in GRHL2 expression and 
also its direct transcriptional targets such as E-cadherin, an important progenitor cell 
adhesion molecule. Taken together, these data suggest a role for GRHL2 in progenitor 
cells and regulation of this gene may be a mechanism by which Notch influences 
progenitor maintenance in the developing pituitary.   
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Notch signaling also regulates the balance of endocrine cell differentiation in the 
developing pituitary. Previous studies suggest that Notch signaling promotes the 
differentiation of the PIT1 lineage comprised of somatotropes, lactotropes and 
thyrotropes, while suppressing differentiation of the corticotrope lineage. Notch is 
thought to promote PIT1 lineage development by regulating the expression of Prop1 
which is required for Pit1 transcription. In contrast, the mechanism by which Notch 
suppresses corticotrope differentiation remains poorly understood. Similar to Notch 
signaling, several studies have demonstrated that the glucocorticoid signaling pathway 
also suppresses corticotrope differentiation. We therefore sought to identify Notch 
regulated genes that are associated with the glucocorticoid signaling pathway. In our 
study, we identify Hsd11b1 as a novel Notch signaling target gene. 11β-HSD1 is widely 
expressed and in the majority of tissues and functions to convert inactive forms of 
glucocorticoids into their biologically active forms.  We hypothesize that Notch may 
induce the expression of Hsd11b1 to increase pituitary-specific levels of active 
glucocorticoids that in turn suppress corticotrope expansion.  
In this work we utilize Notch2 cKO mice, in vivo and in vitro chemical Notch inhibition, 
as well as reporter gene assays in primary pituitary cultures, to demonstrate Hsd11b1 is 
a novel Notch signaling target in the postnatal pituitary. To help elucidate how Notch 
regulation of this gene may influence pituitary development we characterized the 
expression of Hsd11b1 and conducted functional studies in which 11β-HSD1 was 
chemically and genetically inhibited during early pituitary development. Our study 
demonstrates Hsd11b1 is expressed in both pituitary progenitor and endocrine cell 
types. In addition, its expression peaks during early postnatal development, a time in 
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which Notch signaling is crucial for pituitary gland expansion. Our functional studies 
indicate that loss of 11β-HSD1 function results in an increase in corticotrope lineage 
gene expression, similar to the phenotype that is observed in Notch2 cKO mice. Our 
study suggests Notch regulation of Hsd11b1 may be a part of the mechanism by which 
Notch signaling inhibits corticotrope lineage gene expression. Taken together, these 
works help to define the transcriptional network of the Notch signaling pathway in the 
developing pituitary and suggest that Notch signaling can coordinate a vast number of 
targets to regulate pituitary cell fate decisions. 
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CHAPTER 1: Complex Integration of Intrinsic and Peripheral Signaling is 
Required for Pituitary Gland Development1 
ABSTRACT 
The coordination of pituitary development is complex and requires input from multiple 
cellular processes. Recent research has provided insight into key molecular 
determinants that govern cell fate specification in the pituitary. Moreover, increasing 
research aimed to identify, characterize and functionally describe the presumptive 
pituitary stem cell population has allowed for a better understanding of the processes 
that govern endocrine cell differentiation in the developing pituitary. The culmination of 
this research has led to the ability of investigators to recapitulate some molecular and 
cellular aspects of embryonic pituitary development in vitro, the first steps to developing 
novel regenerative therapies for pituitary diseases. In this current review, we cover the 
central molecular players in pituitary stem/progenitor cell function and maintenance, and 
the key molecular determinants of endocrine cell specification. In addition, we discuss 
the contribution of peripheral hormonal regulation of pituitary gland development, an 
understudied area of research.  
INTRODUCTION 
The pituitary is an endocrine gland that dynamically regulates peripheral tissues to 
coordinate fundamental physiological functions such as growth, metabolism, sexual 
maturity and reproduction, pigmentation, the body’s response to stress. The pituitary 
                                            
1 This work is published in its entirety: Edwards, W. and Raetzman L.T. Complex integration of intrinsic 
and peripheral signaling is required for pituitary gland development. Biology of Reproduction. 
https://doi.org/10.1093/biolre/ioy081. In Press.  
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regulates these homeostatic processes by interpreting hypothalamic signals and, in 
response, releases hormones from specialized cells in the anterior pituitary.  These cell 
types include somatotropes that produce growth hormone (GH), thyrotropes that 
produce thyroid stimulating hormone (TSH), lactotropes that produce prolactin (PRL), 
gonadotropes produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH), 
melanotropes that produce melanocyte-stimulating hormone (αMSH) and corticotropes 
that produce adrenocorticotropic hormone (ACTH).  
The use of genetic mouse models has provided novel insight to the molecular 
mechanisms that govern pituitary development and maintenance. These models have 
identified key transcription factors and signaling pathways that are necessary for normal 
pituitary development in both mouse and humans. More recently, the identification of a 
presumptive stem cell/progenitor population in the pituitary gland has provided insight 
into processes that underlie endocrine cell specification and organ homeostasis. These 
cells, identified by their expression of hallmark stemness markers, contribute to 
embryonic and postnatal development of the gland, as well as generation of endocrine 
cell types in response to physiological demands such as puberty, pregnancy and injury. 
The current model of pituitary cell differentiation involves multipotent stem/progenitor 
cells giving rise to a progenitor population that functions as rapidly dividing transit-
amplify cells. These cells then give rise to committed precursor cells that under the 
influence of lineage specific differentiation cues will further mature into the hormone 
producing cells. The progression from stem/progenitor cell to a fully functional endocrine 
cell is dependent on a multifactorial process that integrates several factors including 
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morphogenic factors, cell-to-cell signaling, key transcription factors and hormonal 
influences (Figure 1.1).  
The importance of pituitary stem cell research is to potentially develop cell-based 
treatments for pituitary diseases that result in the absence or decreased levels of 
pituitary hormones such as combined pituitary hormone deficiency (CPHD), traumatic 
brain injury, or after surgical or radiation treatment of pituitary tumors. The goal is to 
treat patients with stem cells that can regenerate the endocrine cells types and restore 
normal pituitary functions. Recent studies have provided evidence that this type of 
advanced treatment is possible however more knowledge about pituitary development 
is necessary to improve these types of medical technologies.  In this review, we aim to 
discuss the major determinants of cell lineage specification in the developing pituitary. 
We will review the well-known as well as newly-discovered factors that are important for 
the function and maintenance of the pituitary stem/progenitor cells, intrinsic factors that 
are necessary for lineage differentiation and the extrinsic factors that contribute to 
pituitary expansion.  
Identification, regulation and function of the stem/progenitor cells population 
Several groups have provided convincing evidence that stem/progenitor cells are 
present in the pituitary and are required for proper development and maintenance of the 
gland. Initial studies identifying this population of cells took advantage of inherent 
properties of stem cells including sphere forming capabilities and side population 
isolation via verapamil sensitive dye efflux assays (Chen et al., 2005; Garcia-Lavandeira 
et al., 2009). These early studies identified a small number of cells that expressed a 
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cohort of genes that are characteristic of stem cell function and maintenance in other 
organs (Chen et al., 2005; Garcia-Lavandeira et al., 2009). Subsequent research 
demonstrated that these populations of cells are capable of differentiating into all of the 
endocrine cell types during neonatal development of the pituitary and contribute to 
gland regeneration in the adult (Andoniadou et al., 2013; Rizzoti et al., 2013) (Table 
1.1).  
Transcription factors that identify the stem cell population 
SOX2  
One of the earliest markers of the stem/progenitor population in the developing pituitary 
is SOX2, a high mobility group box (HMG) transcription factor, known to regulate stem 
cell plasticity during embryonic development (Avilion et al., 2003; Jayakody et al., 2012). 
In humans and mice,  loss of SOX2 in the pituitary results in varying degrees of 
hypopituitarism, demonstrating its essential role in normal pituitary development 
(Goldsmith et al., 2016; Jayakody et al., 2012; Kelberman et al., 2006). SOX2 is 
ubiquitously expressed in proliferating epithelial progenitors throughout Rathke’s Pouch 
(RP) as early as embryonic day 11.5 (e11.5) (Fauquier et al., 2008). In postnatal 
development and in the adult, SOX2 expression decreases and becomes restricted to 
the marginal zone cells that surround the lumen. Interestingly, during early-postnatal 
maturation, clusters of SOX2 positive cells can also be found in the anterior lobe 
parenchyma (Gremeaux et al., 2012). This population of stem/progenitor are regionally 
distinct but remain in a homotypic network with the niche located in the marginal zone 
(Mollard et al., 2012). Studies have shown that all of the hormone producing cell types 
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are derived from a SOX2 expressing precursor cell, providing convincing evidence that 
these cells are in fact stem/progenitors in the pituitary (Andoniadou et al., 2013; 
Fauquier et al., 2008; Rizzoti et al., 2013). SOX2 positive cells also express additional 
progenitor transcription factors including SOX9, a marker of multipotent progenitors in 
other tissues (Chen et al., 2005; Fauquier et al., 2008; Garcia-Lavandeira et al., 2009; 
Rizzoti et al., 2013). During early embryonic development of the gland, the progenitor 
population weakly expresses SOX9 but during postnatal development and in the adult 
the majority of SOX2 cells are also positive for SOX9 (Fauquier et al., 2008).   
PROP1 
The molecular markers that define the stem/progenitor cell population do not appear to 
be constant throughout maturation of the pituitary, suggesting a sequential development 
of the progenitor population and potentially a heterogeneous population of these cells. 
This theory is further supported by the temporal and regionally specific expression of 
Prophet of PIT1 (PROP1), a pituitary specific transcription factor that has also been 
identified as a marker of the stem/progenitor cell population. PROP1, is weakly detected 
in the progenitor cell niche of RP at e11.5, a time in which SOX2 is highly expressed. 
However, by e13.5 the majority of luminal progenitors in RP are positive for both 
PROP1 and SOX2 (Pérez Millán et al., 2016; Sornson et al., 1996; Yoshida et al., 
2009). Beginning in the late embryonic and early postnatal development, PROP1 
positive cells are excluded from the intermediate lobe and become restricted to marginal 
zone and parenchyma of anterior lobe.  In the adult, PROP1 is maintained in the 
marginal zone albeit at a significantly lower level (Garcia-Lavandeira et al., 2009; Pérez 
Millán et al., 2016; Yoshida et al., 2009; Yoshida et al., 2011; Zhu et al., 2015). PROP1 
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mutations are the most common identified cause of hypopituitarism in humans (Cogan 
et al., 1998; Wu et al., 1998). This phenotype is recapitulated Ames dwarf mice 
(Prop1df/df) that harbor a loss of function mutation in PROP1. Characterization of the 
progenitor cell population of these mice have clearly defined a role for PROP1 in 
maintenance and function of the stem/progenitor cell population in the pituitary. 
Prop1df/df mice display an inability of progenitor cells to migrate away from the marginal 
zone indicative of impaired epithelial-to-mesenchymal transition (EMT) (Pérez Millán et 
al., 2016). This is coincident with decreased expression of proliferation markers and 
decreased expression of NOTCH2, an important regulator of stem cell maintenance in 
the developing pituitary. Recently, lineage tracing studies have demonstrated that 
PROP1 expressing cells are able to differentiate into all of the anterior lobe cell types 
(Davis et al., 2016).  These data, in combination with previous studies that observed 
PROP1 in the adult pituitary stem cell niche, solidify PROP1 as a bona fide marker and 
regulator of the stem/progenitor population.  
S100β 
A subset of anterior lobe cells that express the calcium-binding protein β (S100β) have 
been identified as folliculo-stellate cells. These cells are non-granular and display long 
cytoplasmic processes that aid in maintaining cellular networks. S100β positive cells are 
not present during embryonic development and a subset of these cells are thought to 
function as a postnatal specific stem/progenitor cell population. It has been shown that a 
sub-population of folliculo-stellate have colony forming capacity and the ability to 
differentiate into endocrine cell types (Higuchi et al., 2014b; Lepore et al., 2007). In 
addition, multiple studies have demonstrated that S100β is detected in cells that 
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express other stem cell makers including SOX2 and PROP1, although not exclusively. 
Interestingly, it appears that there is a progressive increase in SOX2/S100β positive 
cells as the pituitary develops, with approximately 85% of SOX2 cells co-expressing 
S100β in the adult rat (Fauquier et al., 2008; Garcia-Lavandeira et al., 2009; Yoshida et 
al., 2011). The fact that these cells are morphologically, temporally and regionally 
distinct from other stem/progenitor cell populations in the pituitary may suggest that they 
constitute a specialized progenitor cell niche.  
Stem cell niche factors 
The maintenance of the stem/progenitor cell population is not only dependent on the 
expression of transcription factors that regulate cellular plasticity but also on the 
components of their specialized microenvironments. Factors that compose the stem cell 
niche are tissue specific and often include structural proteins that make up the 
extracellular matrix (ECM), cell surface receptors that function in cell-to-cell 
communication, soluble factors, supportive cells and cell surface proteins. In the 
pituitary, relatively little is known about the niche components that contribute to 
stem/progenitor cell maintenance and function. However, a few factors that contribute to 
the structural integrity and cell-cell interactions in the pituitary stem/progenitor cell niche 
have been investigated.  
Notch Signaling 
Notch signaling is a cell-to-cell contact dependent pathway that regulates stem cell 
maintenance and cell fate choice in many organs including the developing pituitary. 
Activation of the pathway requires a cell expressing a Notch ligand to activate a Notch 
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receptor on an adjacent cell. The interaction of the receptor and the ligand results in two 
successive proteolytic cleavages, the first by ADAM10 which releases the Notch 
extracellular domain of the receptor. Subsequently, the second cleavage by gamma 
secretase releases the Notch intracellular domain (NICD), which translocates to the 
nucleus and regulates transcription of target genes via binding of the co-factor protein 
RBPJ. Core components of the Notch signaling pathway define the stem/progenitor cell 
compartment of the developing pituitary. The receptors Notch2 and Notch3, the ligands 
Jag1 and Dll1 as well as the canonical downstream target genes Hes1 and Hey1 are 
detected in Rathke’s pouch in proliferating progenitors during early pituitary 
development (Raetzman et al., 2004; Raetzman et al., 2007; Zhu et al., 2006). During 
postnatal development and in the adult, expression of these genes is down regulated 
but maintained in the presumptive stem cell compartment, following an expression 
pattern similar to that of other stem cell makers.   
Genetic mouse models have provided useful insight into role of Notch signaling in the 
developing pituitary. Conditional loss of either the essential Notch cofactor Rbpj, or the 
notch effector gene Hes1 during embryonic pituitary development results in a 
hypoplastic pituitary, decreased proliferation of pituitary progenitors and premature cell 
cycle exit (Monahan et al., 2009; Zhu et al., 2006). A similar progenitor phenotype was 
observed in mice with a conditional loss of the Notch2 receptor (Notch2 cKO) 
specifically during postnatal pituitary development. These mice display decreased 
progenitor proliferation, and a decrease in expression of the well-known progenitor cell 
markers SOX2 and SOX9 as well as the novel pituitary progenitor marker grainyhead 
like 2 (GRHL2) (Edwards et al., 2016). Additionally, pituitary stem cells in culture rely on 
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Notch signaling because loss of Rbpj or treatment with DAPT, a gamma secretase 
inhibitor, results in the inability of progenitors to expand and form pituispheres (Zhu et 
al., 2015).  These findings suggest that Notch may directly regulate the expression 
transcription factors necessary for stem cell plasticity in the pituitary, as all of these 
have been shown to be directly regulated by Notch in other systems (Li et al., 2012) . 
Furthermore, both mice with a loss of Notch2 or Rbpj have decreased expression of 
Prop1, which was also shown to be a direct Notch target in the pituitary (Nantie et al., 
2014; Zhu et al., 2006). PROP1 is also thought to be a regulator of Notch2 expression 
suggesting a reciprocal relationship between these two factors (Mortensen et al., 2011; 
Pérez Millán et al., 2016; Raetzman et al., 2004; Ward et al., 2005). In agreement, 
overexpression of Notch in the pituitary inhibits differentiation of the hormone producing 
cell types and results in ectopic expression of SOX2 (Goldberg et al., 2011).  
Active Notch signaling may also regulate the expression of cell adhesion molecules that 
are crucial for the maintenance of the stem/progenitor cell niche in the pituitary. Gene 
expression studies have shown that the pituitary progenitor population is enriched for 
both Notch signaling components and E-cadherin, a cellular adhesion molecule, known 
to be an important regulator of stem-cell niche adhesion (Chen et al., 2013a; Fauquier 
et al., 2008; Garcia-Lavandeira et al., 2009).  Decreased expression of E-cadherin was 
observed in Notch2 cKO pituitaries, specifically in the marginal zone of the intermediate 
lobe. Interestingly, an almost complete loss of SOX2 positive cells was observed in this 
region, indicating a severe disruption in the intermediate lobe progenitor niche (Edwards 
et al., 2016). Additional in vitro studies have established a link between Notch signaling 
and E-cadherin expression. Inhibition of cell-to-cell contact via down regulation of E-
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cadherin in pituitary monolayer cell culture results in decreased expression of the 
canonical Notch target, Hes1 (Batchuluun et al., 2016). These findings may indicate a 
reciprocal relationship between pituitary niche adhesion molecules and Notch signaling 
activity.  
Taken together, these studies demonstrate that Notch signaling is necessary for 
pituitary stem/progenitor maintenance and expansion. In particular, it appears that 
Notch signaling not only regulates the expression of transcription factors necessary for 
stem cell self-renewal but also adhesion molecules that modulate the stem cell 
microenvironment.  
CXADR and ECM protein expression  
Additional components that contribute to the stem cell niche have been relatively 
unexplored, but a series of studies have highlighted novel factors that may be important 
in the developing pituitary. Expression of Coxsackievirus and adenovirus receptor 
(CXADR), a transmembrane protein that associates with tight junction complexes, was 
recently identified in the progenitor cell compartment throughout pituitary development 
(Chen et al., 2013b). CXADR expression has been observed in neuroepithelial cells of 
the central nervous system and it thought to facilitate maturation of tight junctions during 
development (Hotta et al., 2003). However, the function of CXADR in the developing 
pituitary stem/progenitor cells remains unknown.  
Extracellular matrix proteins are important for the proper development, morphology and 
tumorigeneses in the pituitary (Paez-Pereda et al., 2005). Little is known about the 
specific ECMs that contribute to the stem/progenitor cell niche in the pituitary, but a few 
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studies have demonstrated that ECMs may contribute to the function and maintenance 
of these cells. In vitro studies show S100β positive cells interact with various ECM 
proteins including laminins, collagens and integrins and these interactions regulate 
proliferation and morphological characteristics of these cells (Horiguchi et al., 2010a; 
Horiguchi et al., 2010b). In addition, the ontogeny of laminin chain expression was 
examined during neonatal pituitary development. Interestingly, Laminin 5α which is 
present in pluripotent embryonic stem cells, was detected in Rathke’s pouch as wells in 
the marginal zone during postnatal pituitary development (Ramadhani et al., 2014). 
These data suggest ECM components are important regulators of the stem/progenitor 
compartment in the developing pituitary.  
Transcription factors that drive differentiation and lineage specification in the developing 
pituitary 
As pituitary development progresses, stem/progenitor cells must exit the cell cycle and 
differentiate into one of the hormone producing cell types. The processes of adopting a 
specific cell fate is facilitated by the expression of transcription factors that promote 
lineage specification. The use of genetically engineered mouse models and naturally 
occurring spontaneous mutations in both mice and humans have led to the discovery of 
several genes that are crucial for endocrine cell specification and function.  
Corticotrope and melanotropes  
The terminal differentiation of the two proopiomelanocortin (POMC) expressing cell 
types, melanotropes which cleave POMC into αMSH and corticotropes which cleave 
POMC into adrenocorticotropic hormone (ACTH), is driven by the expression of the T-
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box transcription factor, TPIT, also known as TBX19. In humans, inactivating mutations 
in TPIT are associated with isolated adrenocorticotropic hormone deficiency (IAD), 
eluding the importance of TPIT in the proper differentiation of the POMC lineage in the 
pituitary. TPIT expression is detected in the caudoventral region of Rathke’s Pouch as 
early as e12.5 before the onset of POMC expression (Lamolet et al., 2001; Pulichino et 
al., 2003). Studies have demonstrated that TPIT regulates POMC transcription in 
corticotropes through synergistic interactions with other transcription factors including 
the homeodomain transcription factor PITX1, the basic helix-loop-helix factor NeuroD1, 
and the ETS factor ETV1 (Budry et al., 2011; Poulin et al., 1997; Poulin et al., 2000). 
Tpit null mice display a decrease in the number of POMC expressing corticotropes but 
do express other corticotrope specific genes indicating a defect in the later stages of 
differentiation.  In the absence of Tpit, the intermediate lobe is hypoplastic and 
melanotropes adopt an alternate cell fate indicated by the expression of αGSU and SF1, 
markers of thyrotropes and gonadotropes (Pulichino et al., 2003). Tpit overexpression in 
the αGSU expressing cells initiates corticotrope differentiation in these cells and as a 
result expression of LHβ, FSHβ and SF1 are decreased (Lamolet et al., 2001; Pulichino 
et al., 2003). These data demonstrate a role for TPIT not only in the promotion of 
corticotrope differentiation but also as an active suppressor of other lineage specific 
makers. 
Aside from the role of Notch signaling as regulator of stem/progenitor cell maintenance, 
it functions as a binary cell fate determinant in the developing pituitary. Specifically, it 
appears that Notch signaling regulates the balance between the TPIT and PIT1 
lineages. Models of reduced Notch signaling in the pituitary show precocious 
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differentiation of corticotrope cells (Nantie et al., 2014; Zhu et al., 2006). In addition, 
constitutive activation of the Notch in POMC expressing cells prevents differentiation of 
melanotropes and corticotropes. This inability to differentiate is marked by increased 
expression of SOX2 in the intermediate lobe indicating these cells are confined to a 
progenitor like state. These studies demonstrate that Notch signaling is necessary to 
suppress aberrant corticotrope expansion and down regulation of this pathway is 
necessary for melanotrope and corticotrope differentiation.  
Although TPIT is a common factor necessary for terminal differentiation in both 
corticotropes and melanotropes, additional lineage specific factors such as NeuroD1 
and PAX7 have been shown to regulate development and maturation of these cell 
types. NeuroD1 is dynamically expressed in pituitary corticotropes and is not only a 
regulator of Pomc transcription but also is implicated in the differentiation of the 
corticotrope lineage. Loss of NeuroD1 results in a minor delay in corticotrope 
differentiation that is recovered by e16.5, indicating that it may contribute to early 
differentiation of this lineage (Poulin et al., 1997).  PAX7, a pioneering transcription 
factor, is an important regulator of melanotrope identity and melanotrope-specific POMC 
transcription. PAX7 is exclusively detected in the intermediate lobe cells that co-express 
Tpit beginning at e15.5 (Budry et al., 2012). In Pax7 knockout mice pituitaries, 
melanotropes appear to adopt a corticotrope cell fate indicated by the down regulation 
of genes enriched in melanotropes, including Pc2 and Drd2, and a subsequent up 
regulation of genes specific to corticotropes including Nr3c1, NeuroD1 and Crhr1. In 
addition, these studies demonstrate that PAX7 actually is not the main driver of 
melanotrope differentiation, rather is it necessary to allow accessibility of melanotrope 
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specific genes to other transcription factors that regulate differentiation such as 
TPIT(Budry et al., 2012; Mayran et al., 2018).  
It is also important to note that cellular localization and cell network formation are 
important for the function and development of the POMC lineage. Loss of the cellular 
adhesion molecule N-cadherin (Cdh2) in POMC expressing cells results in disrupted 
intermediate lobe boundaries, mis-localization of corticotropes and an overall decrease 
in Pomc levels (Himes et al., 2011). Additional studies have demonstrated the adaptor 
protein NUMB, known for its role in degradation of the Notch receptors and cell 
adhesion, is also necessary for intermediate lobe organization and progenitor cell 
localization (Moran et al., 2011). Taken together, these studies identify additional 
regulatory proteins that contribute to the proper development of the POMC lineage.  
PIT1 lineage: somatotropes, lactotropes and thyrotropes 
PIT1, a POU homeodomain protein, is a major determinant of terminal differentiation of 
three hormone producing cell types: somatotropes, lactotropes and thyrotropes. 
Mutations in PIT1 in both humans and mice results in combined pituitary hormone 
deficiency (CPHD), establishing an important role of PIT1 in pituitary development (Li et 
al., 1990). Genetic mouse models of PIT1 deficiency, including the Snell’s dwarf and 
Jackson dwarf, exhibit pituitary hypoplasia coincident with a decrease in the number 
somatotropes, lactotropes and thyrotropes (Camper et al., 1990). These phenotypic 
changes are observed only during postnatal pituitary development suggesting that PIT1 
is not required for the initial differentiation of these linages but rather it is necessary for 
postnatal expansion. PIT1 is first detected at e13.5 and increases in expression into 
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adulthood as endocrine cells undergo major waves of expansion (Simmons et al., 
1990). In terminally differentiated cells, PIT1 transcriptionally regulates the expression 
of Gh, Tshb and Prl as well as the hypothalamic signaling receptor, growth hormone 
releasing hormone receptor (Ghrhr) (McElvaine et al., 2007; Rhodes et al., 1994). The 
Notch signaling pathway and PROP1 are currently thought to be the primary regulators 
of Pit1 expression. Ames dwarf mice and mouse models of reduced Notch signaling 
exhibit a similar decrease in the number of somatotropes, lactotropes and thyrotropes in 
the developing pituitary (Nantie et al., 2014; Zhu et al., 2006). PROP1 is a direct 
transcriptional activator of Pit1 expression while Notch is thought to exert its effects on 
Pit1 indirectly through regulation of PROP1 expression (Andersen et al., 1995). 
Although it has been shown that PIT1 is necessary for terminal differentiation of 
somatotropes, lactotropes and thyrotropes, the molecular mechanisms that govern 
specification of these different cells remains elusive.  
Somatotropes 
The bHLH factor NeuroD4, a downstream target of PIT1 necessary for somatotrope 
differentiation, is expressed by e13.5 in the mouse. Somatotropes are severely 
decreased in NeuroD4 null mice embryonically. Although somatotrope differentiation 
mildly recovers during postnatal development, these mice fail to express GHRHR and 
display dwarfism (Zhu et al., 2006). The postnatal pituitary hypoplasia due to loss of 
somatotrope expansion in NeuroD4 null mice is likely due in part to loss of hypothalamic 
input in this cell type. This is supported by a similar hypoplasia phenotype observed in 
little mice (Ghrhrlit/lit) which harbor a point mutation in GHRHR (Eicher and Beamer, 
1976). More recently, it was demonstrated that FOXO1, the forkhead box transcription 
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factor, is also important for embryonic somatotrope differentiation. Conditional loss of 
Foxo1 is the developing pituitary results in a decrease of Gh and Ghrhr mRNA levels, 
although adult animals appear unaffected. In addition, FOXO1 may be an upstream 
regulator of NeuroD4 as its expression is reduced embryonically in these mice (Kapali 
et al., 2016).  
Thyrotropes 
Two populations of thyrotrope cells are present during pituitary organogenesis: the first 
to appear is a PIT1 independent lineage located in the rostral tip specifically during 
embryonic development and a second PIT1 dependent lineage. Little is known about 
the regulation and function of rostral tip thyrotropes however, factors have been 
identified that regulate the PIT1 dependent lineage. During early gland specification 
events a set of common genes are expressed that are necessary for both thyrotrope 
and gonadotrope specification. These include two transcription factors, FOXL2 and 
GATA2, as well as Cga, a gene that encodes for αGSU, the common α-glycoprotein 
subunit of TSH and the gonadotropins LH and FSH. FOXL2 regulates expression of 
αGSU and is the earliest maker of thyrotrope and gonadotrope specification (Ellsworth 
et al., 2006). Its expression is observed ventrally in RP as early as e10.5 before the 
onset of hormone expression in these lineages at e12 (Treier et al., 1998). Loss-of-
function studies have identified GATA2 as a regulator of differentiation of both 
thyrotropes and gonadotropes. Expression of a dominant negative form of GATA2 or a 
pituitary specific knockout of Gata2 inhibits terminal differentiation of thyrotropes 
indicated by reduced express if Tshb (Charles et al., 2006; Dasen et al., 1999; 
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Kashiwabara et al., 2008). In addition, Pit1 is increased in these pituitaries suggesting 
that PIT1 alone is not sufficient for the proper expression of TSHβ. In support of this 
observation, these studies also demonstrated that GATA2 and PIT1 act synergistically 
to transcriptionally regulate Tshb expression.  
Lactotropes 
Terminally differentiated lactotropes marked by the expression of prolactin (PRL) are 
detected by e15.5 in mice (Dollé et al., 1990; Matsubara et al., 2001). Although 
lactotropes are detected before birth, lactotrope cell number remains low during 
embryonic pituitary development, with the majority of lactotrope expansion occurring 
during postnatal development. Interestingly, studies using targeted ablation of growth 
hormone producing cells demonstrated a significant decrease in lactotrope cells as well, 
indicating that mature lactotropes may be derived from a precursor cell that expressed 
growth hormone referred to as somatolactotropes (Behringer et al., 1988; Borrelli et al., 
1989). However, these studies are somewhat controversial as lineage tracing studies 
suggest that the majority of lactotropes are derived from pituitary progenitor cells (Fu et 
al., 2012; Luque et al., 2007).Relatively little is known about the factors driving further 
lactotrope specification. More recently, ZBTB20, a zinc finger containing transcription 
factor, was shown to be important for lactotrope specification. ZBTB20 null mice exhibit 
postnatal pituitary hypoplasia due to an absence of terminally differentiated lactotropes 
and a decreased number of somatotropes. These studies also demonstrate ZBTB20 as 
a transcriptional regulator of Prl expression (Cao et al., 2016). In addition, it has been 
shown that lactotrope terminal differentiation and proliferation are regulated by 
hormonal signals such as estrogens. The decrease in PRL expression and lactotrope 
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cell number observed in estrogen receptor alpha (ERα) disrupted mice (Esr1-/-) 
suggests estrogenic signaling is necessary for maturation of lactotrope cells and may 
provide a mechanism to devise terminally differentiated lactotropes from 
somatolactotrope precursor cells (Ogasawara et al., 2009; Scully et al., 1997). It has 
also been demonstrated that shortly after pregnancy there are an increased number of 
proliferating lactotropes and increased levels of circulating PRL, thought to be triggered 
by estrogen. However is it unclear if the primary mechanism of increased PRL in 
response to estrogen in this capacity is due to increased lactotrope number or 
hypertrophy (Yin and Arita, 2000).  
Gonadotropes 
As mentioned previously transcription factors GATA2 and FOXL2 are early markers of 
gonadotrope cells. FOXL2 interacts with Smad proteins to directly regulate transcription 
of Fshb in gonadotropes (Li et al., 2017; Tran et al., 2011; Wang and Bernard, 2012). 
The necessity of FOXL2 in FSH expression is exemplified by FSHβ deficiency and 
subsequent reduced fertility in mice with a conditional deletion of Foxl2 in gonadotropes 
(Ellsworth et al., 2006; Tran et al., 2013). GATA2 is not necessary for differentiation of 
this lineage but is important for function as reduced GATA2 expression is also 
associated with reduced FSH levels (Charles et al., 2006). GATA2 is also a positive 
regulator of gonadotrope specific genes including the orphan nuclear receptor NR5A1 
(also known as SF1)(Dasen et al., 1999). NR5A1 expression is detected starting at 
e13.5, and is one of the first gonadotrope specific makers before the onset of LHβ and 
FSHβ (Ingraham et al., 1994). The loss of Nr5a1 globally or in the pituitary specifically, 
results in decreased basal levels of gonadotropins, however hormone expression can 
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be induced in response to the hypothalamic stimulus gonadotropin releasing hormone 
(GnRH) (Zhao et al., 2001). It has also been demonstrated that GnRH mediated 
transcriptional induction of Lhb requires synergism between SF1 and the transcription 
factors EGR1 and PITX1 both of which are known regulators of gonadotropins 
(Tremblay and Drouin, 1999).  
The Notch signaling pathway has been also implicated in gonadotrope differentiation. 
Overexpression of the Notch downstream target Hes1 and constitutively active Notch in 
Cga expressing cells results in delayed gonadotrope differentiation (Raetzman et al., 
2006; Raetzman et al., 2007). Notch2 cKO mice have increased expression of both 
Nr5a1 and Lhb but with no  increase in gonadotrope number (Nantie et al., 2014). In 
contrast, no apparent gonadotrope phenotype was observed in mice with conditional 
loss of Rbpj, the essential Notch cofactor (Zhu et al., 2006). These studies indicate that 
active Notch signaling is sufficient to suppress gonadotrope differentiation however is 
does not appear to affect gonadotrope specification.   
Hormonal influence on pituitary differentiation 
The pituitary gland is a major hub of endocrine function and as such it is under feedback 
regulation from peripheral tissues. The release of hormones such as sex steroids, 
thyroid hormones, glucocorticoids and insulin-like growth factor 1 (IGF-1), from the 
corresponding peripheral tissues is the primary mechanism of feedback to the pituitary 
to ensure homeostatic balance. The endocrine cells of the pituitary are therefore 
functionally controlled by peripheral hormones, but these hormones may also regulate 
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the differentiation and specification of cells in the pituitary. Here we discuss the most 
well studied examples of peripheral hormones influence on pituitary development.   
In response to activation of hypothalamic-pituitary-adrenal axis (HPA), pituitary 
corticotropes release adrenocorticotropic hormone (ACTH) which acts on the adrenal 
gland and subsequently results in the release of glucocorticoids (GCs) that regulate 
peripheral tissues and negatively feedback to both the pituitary and hypothalamus. It is 
well established that GCs regulate the response to stress in the adult animal, but 
evidence suggests glucocorticoid signaling also regulates corticotrope differentiation. In 
adult mice it has been demonstrated that corticotrope cell number is increased in 
response to adrenalectomy (Nolan and Levy, 2006). The increase in cell number and 
the ability of dexamethasone to attenuate this response indicates that glucocorticoids 
are capable of regulating corticotrope differentiation. Furthermore, mice with a 
conditional deletion of the glucocorticoid receptor (Nr3c1PomcCre) in the pituitary have 
increased Pomc mRNA levels and an apparent increase in corticotrope number at 
postnatal day 6 (Schmidt et al., 2009). Taken together, these studies demonstrate a 
suppressive role of GCs in corticotrope differentiation in the adult and postnatal 
pituitary. In contrast, GCs have been shown to positively regulate somatotrope 
differentiation (Vakili and Cattini, 2012). Studies in rat and chicken embryos 
demonstrate that in vivo exposure to glucocorticoids results in an increase in Gh levels 
and premature differentiation of somatotropes (Ellestad et al., 2015; Nogami and 
Tachibana, 1993; Porter, 2005).  Coincidentally, terminal differentiation of somatotropes 
coincides with the onset of HPA axis activity during late embryonic development (Wood 
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and Walker, 2015). These studies indicate that GCs regulate differentiation of the both 
corticotropes and somatotropes during pituitary development.  
Similar to the regulation of corticotrope number by GCs, peripheral hormones from 
target organs also regulate somatotrope differentiation. Secretion of growth hormone 
from somatotropes stimulates the production of IGF-1 from the liver and feeds back 
negatively to hypothalamic-pituitary axis to suppresses GH release. Studies in IGF-1 
knockout mice demonstrate that loss of IGF-1 results in increased somatotrope number 
in adult mice, indicating IGF-1 is necessary to maintain the correct number of 
somatotropes (Hikake et al., 2009).  
As mentioned previously, the most well-known example of hormonal regulation on 
cellular differentiation in the pituitary are the effects of estrogen on lactotrope 
differentiation. However, other endocrine cells types in the pituitary are regulated by 
estrogenic signaling. In adults, it is well established that estrogens play a role in 
regulating gonadotropin secretion, but studies also indicate a role for estrogens during 
gonadotrope cell development. In the chick embryo, exposure to estradiol promotes an 
increase in gonadotrope differentiation and proliferation (Wu et al., 2009). In support of 
this observation, adult rodents treated with tamoxifen, an estrogen receptor modulator, 
have an increased number of gonadotropes cells (Aguilar et al., 2006). Furthermore, 
target organ ablation studies in which mice are gonadectomized show an increase in 
the gonadotrope population, most like due to mobilization of the stem/progenitor cell 
population indicating that peripheral hormonal signals regulate cell number in the 
pituitary (Nolan and Levy, 2006).  
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The influence of estrogens on pituitary development suggests that it may also be 
sensitive to exogenous estrogenic compounds. Specifically, exposure to the endocrine 
disrupting chemical (EDC) Bisphenol A (BPA) during critical windows of development 
affects gonadotrope differentiation. Female neonatal mice exposed to BPA or estradiol 
during gestation have increased gonadotrope cell numbers (Brannick et al., 2012). In 
addition, mice exposed to BPA and estradiol during postnatal development show 
decreased expression of sexually dichotomous genes in the pituitary, indicating 
postnatal sensitivity to hormonal regulation (Eckstrum et al., 2016). Several studies 
have also demonstrated that exposure to BPA during critical windows of development 
results in HPA axis dysfunction in adult mice (Chen et al., 2014; Chen et al., 2015; Zhou 
et al., 2015). The pituitary contribution to this dysfunction remains unclear but studies 
have reported changes in pituitary Crhr1 and Pomc mRNA levels (Panagiotidou et al., 
2014). Changes in gene expression and cell number after exposure to EDCs further 
demonstrate that the pituitary is sensitive to hormonal regulation during early 
developmental periods. While the mechanisms/contribution of hormonal regulation has 
been relatively unexplored in the developing pituitary, this mode of regulation is 
important for gland development.  
Conclusion 
Current research has provided a substantial basis for understanding the molecular 
mechanisms that dictate pituitary cell fate decisions and organ homeostasis. However, 
in order to achieve the goal of using stem cell derived treatment for pituitary disease, 
the contributing players in the stem/progenitor cell niche and peripheral regulation of 
pituitary development will need to be further dissected. Future research using single cell 
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genomic approaches will be helpful in the identification of transitional cell types and 
novel molecular determinants that coordinate differentiation of the endocrine cell types. 
These studies will aid the field in identifying the developmental progression of each of 
the endocrine cell types thus allowing researchers recapitulate pituitary development.   
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TABLE 
 
 
Table 1.1: Transcription factors and niche components identified in the pituitary 
progenitor compartment 
Marker Gene Name Reference 
Transcription Factors  
Sox2 SRY-box containing gene 2 (Andoniadou et al., 2013; Fauquier et al., 2008; Rizzoti et al., 2013) 
Sox9 SRY-box containing gene 9 (Castinetti et al., 2011; Chen et al., 2005; Fauquier et al., 2008; Garcia-
Lavandeira et al., 2009; Rizzoti et al., 2013) 
Prop1 Prophet of Pit1, Paired-Like Homeodomain 
Transcription factor 
(Garcia-Lavandeira et al., 2009; Pérez Millán et al., 2016; Sornson et al., 
1996; Yoshida et al., 2009; Yoshida et al., 2011; Zhu et al., 2015) 
Grhl2 Grainyhead Like Transcription Factor 2 (Edwards et al., 2016) 
Oct4 (Pou5f1) Octamer-Binding Protein 4 (Chen et al., 2005; Chen et al., 2009; Garcia-Lavandeira et al., 2009) 
Prrx1 Paired Related Homeobox Protein 1 (Higuchi et al., 2014a; Higuchi et al., 2015) 
Prrx2 Paired Related Homeobox Protein 2 (Higuchi et al., 2014a; Higuchi et al., 2015) 
Ctnnb1 (β- 
Catenin)  
Cadherin-Associated Protein Beta (Gaston-Massuet et al., 2011; Olson et al., 2006) 
Notch Signaling components  
Hes1 Hairy and enhancer of split 1 (Chen et al., 2006; Nantie et al., 2014; Raetzman et al., 2004; Zhu et al., 
2006) 
Hey1 Hairy/enhancer-of-split related with YRPW 
motif 1 
(Chen et al., 2009; Nantie et al., 2014) 
Dll1 Delta Like Canonical Notch Ligand 1 (Nantie et al., 2014; Raetzman et al., 2004; Zhu et al., 2006; Zhu et al., 
2015) 
Jag1  Jagged 1  (Chen et al., 2006; Chen et al., 2009) 
Notch1 Notch 1 (Chen et al., 2005; Chen et al., 2006; Chen et al., 2009) 
Notch2 Notch 2  (Chen et al., 2006; Chen et al., 2009; Nantie et al., 2014; Raetzman et al., 
2004; Zhu et al., 2006; Zhu et al., 2015) 
Notch3  Notch 3 (Chen et al., 2006; Chen et al., 2009; Zhu et al., 2006) 
Extracellular Receptors / Cell Surface Antigens 
Ly6a (Sca1) Stem cell antigen 1 (Chen et al., 2005; Chen et al., 2006; Chen et al., 2009) 
SSEA-4 stage-specific embryonic antigen-4 (Garcia-Lavandeira et al., 2009) 
Cxadr  Coxsackievirus and adenovirus receptor (Garcia-Lavandeira et al., 2009; Yoshida et al., 2016) 
Cxcr4 C-X-C Motif Chemokine Receptor 4 (Chen et al., 2009; Horiguchi et al., 2012; Yoshida et al., 2016) 
Lgr5 Leucine Rich Repeat Containing G 
Protein-Coupled Receptor 5 
(Chen et al., 2009) 
CD44 CD44 antigen (Chen et al., 2009) 
Gfra2 GDNF Family Receptor Alpha 2 (Garcia-Lavandeira et al., 2009) 
Cellular Adhesion molecules  
Cdh1 (E-
cadherin)  
Calcium-Dependent Adhesion Protein (Edwards et al., 2016; Fauquier et al., 2008; Garcia-Lavandeira et al., 2009) 
Lama5 (Laminin 
5α) 
Laminin Subunit Alpha 5 (Ramadhani et al., 2014) 
Itgb1 (Integrin 
1β) 
Integrin Subunit Beta 1 (Horiguchi et al., 2012) 
Other  
S100b S-100 Protein Subunit Beta (Chen et al., 2005; Fauquier et al., 2008; Garcia-Lavandeira et al., 2009; 
Lepore et al., 2007; Yoshida et al., 2011; Yoshida et al., 2016) 
Nestin  Nestin (Chen et al., 2005; Chen et al., 2009) 
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FIGURE 
Figure 1.1: Coordination of pituitary progenitor differentiation in to the endocrine cell types requires both intrinsic and 
extrinsic factors. During pituitary gland develop of the hormone producing cell types are derived from a common 
progenitor cell. The balance of progenitor cell maintenance and differentiation in necessary for proper gland development. 
Maintenance of the progenitor cell compartment is dependent on transcription factors and niche components. Endocrine 
cell differentiation and cell number is coordinated by both transcription factors and peripheral hormones.  
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CHAPTER 2: Specific Aims of Thesis 
The pituitary gland regulates important physiological functions including growth, 
metabolism, and sexual reproduction by integrating and responding to hormonal signals 
from the nervous and endocrine organs. These vast functions of the pituitary are 
executed through distinct cells types of the anterior pituitary including corticotropes, 
somatotropes, lactotropes, thyrotropes and gonadotropes. Pituitary disease such as 
hypopituitarism, arise from disruption in the development or function of the different 
pituitary cell types. Prevalence of hypopituitarism is 45.5 per 100,000 individuals (Regal 
et al., 2001). While genetic causes such as mutations in key transcription factors have 
been identified in a subset of hypopituitarism cases, the etiology of approximately 80% 
of cases remains unknown (Castinetti et al., 2015).  To identify the mechanisms of 
pituitary disorders such as these and to treat patients appropriately, it is important to 
elucidate the genes and pathways that direct pituitary development and cell fate choice. 
Currently the processes controlling commitment and specification of the different 
pituitary cell lineages are poorly understood. However, our lab has identified the Notch 
signaling as an important regulator of pituitary progenitor proliferation and maintenance 
as well as a regulator of endocrine cell fate decisions. Our analysis of Notch2 
conditional knockout (cKO) mice demonstrate that Notch2 is necessary to maintain 
pituitary progenitors, promote differentiation of somatotropes, thyrotropes and 
lactotropes and restrain aberrant corticotrope expansion, specifically in the postnatal 
pituitary.  While our studies identified the role of Notch signaling in the developing 
pituitary, the underlying mechanism by which Notch signaling controls the fate of these 
cell lineages still remains elusive.  
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The long-term goal of this study was to identify novel downstream targets of the Notch 
signaling pathway that influence cell fate decisions in the pituitary to help elucidate a 
potential mechanism by which the Notch signaling pathway regulates pituitary 
development. To identify potential Notch targets, we conducted a microarray analysis 
comparing postnatal Notch2 cKO and control mice pituitaries. We identified two novel 
genes that are down regulated in Notch2 cKO pituitaries compared to controls. The first, 
Grainyhead-like 2 (GRHL2), is present in epithelial progenitors in many tissues where it 
regulates cellular proliferation, differentiation and migration (Chen et al., 2010; Chen et 
al., 2016; Gao et al., 2015; Varma et al., 2012). Due to its ability to regulate processes 
involved in stem/progenitor cell maintenance, we proposed that Notch regulation of 
Grhl2 may be one potential mechanism by which this pathway controls pituitary 
progenitor maintenance. The second target we identified was 11-beta hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), an enzyme that functions to regulate intracellular 
concentrations of active glucocorticoid in numerous tissues including the liver, kidney 
and heart (Reviewed in Chapman K.  Seckl J., 2013). This enzyme is of interest 
because glucocorticoids are known to regulate corticotrope function and differentiation. 
It is well established that glucocorticoids regulate Pomc transcription in the pituitary via 
the glucocorticoid receptor (GR), and studies using GR conditional knockout mice 
(Nr3c1fl/flPomc+/Cre) show that loss of glucocorticoid signaling in the pituitary results in an 
increase in mRNA levels of Pomc and apparent increase corticotrope cell number in 
postnatal pituitary (Schmidt et al., 2009). Taken together this data suggests that 11β-
HSD1 may be a downstream target of the Notch signaling pathway that influences 
corticotrope cell fate in the developing postnatal pituitary. The objective of this thesis 
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was to identify novel downstream Notch targets in the postnatal pituitary, elucidate the 
mechanism by which Notch regulates these targets and characterize their expression 
and function to determine how their regulation by Notch may contribute to pituitary 
development. Our central hypothesis was that the Notch signaling pathway directly 
regulates the expression of novel targets that function to control progenitor maintenance 
and cell fate choice in the postnatal pituitary. To address these hypotheses, we 
conducted the following studies: 
Aim1) Determine mechanism by which Notch regulates Grhl2 expression and 
characterize expression of GRHL2 in the postnatal pituitary (Chapter 3). Working 
hypothesis: GRHL2 is expressed in pituitary progenitors and is directly regulated by 
Notch signaling in the postnatal pituitary. To determine Notch regulation of Grhl2, we 
examined expression of Grhl2 in Notch2 cKO mice in early postnatal pituitary 
development. In addition, we dosed postnatal mice in vivo with DAPT, a gamma 
secretase inhibitor, to determine if Notch regulation of Grhl2 can occur specifically 
during postnatal development. To determine the kinetics of Notch regulation of Grhl2, 
we monitored expression of Grhl2 in pituitary explant cultures treated with DAPT and 
performed DAPT washout assays. Finally, we demonstrate that GRHL2 is localized 
primarily in progenitor cells by preforming immunohistochemistry colocalization studies 
with GRHL2 and additional pituitary progenitor markers.  
Aim2) Determine the mechanism by which Notch regulates Hsd11b1 expression in the 
postnatal pituitary (Chapter 4).  Working hypothesis: Notch regulates Hsd11b1 
expression directly via a complex containing the Notch2 intracellular domain and the 
DNA binding co-factor, RBPJ. To determine the mechanism of Notch regulation of 
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Hsd11b1, we examined expression of Hsd11b1 in mice with a conditional loss of Notch2 
in early postnatal pituitary development. In addition, we treated postnatal mice in vivo 
and in vitro with DAPT to determine if Notch regulation of Hsd11b1 can occur 
specifically during postnatal development at the level of the pituitary. Finally, we 
identified putative RBPJ sites in the regulatory regions of the Hsd11b1 gene. We utilized 
reporter gene activity studies to demonstrate the functionality of these sites in the 
presence of active Notch signaling in primary pituitary progenitor cultures.  
Aim3) Determine the function of 11β-HSD1 in pituitary development (Chapter 4). 
Working hypothesis:  11β-HSD1 regulates corticotrope specification in the postnatal 
pituitary through its ability to alter intracellular levels of active glucocorticoids. To 
determine how loss of 11β-HSD1 activity will impact pituitary development we 
performed gene and protein expression analysis in pituitary explant cultures treated with 
a chemical inhibitor of 11β-HSD1 and pituitaries generated from mice with a conditional 
loss of Hsd11b1 expression in Pomc expressing cells (Hsd11b1 cKO). In addition, we 
performed restraint stress studies to determine if Hsd11b1 cKO displayed altered HPA 
axis function.   
These studies helped to elucidate the mechanism by which the Notch signaling pathway 
is able to direct cell fate choice in the developing pituitary and may lead to therapies for 
pituitary diseases of inappropriate cell number.  
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CHAPTER 3:  Identification of a Novel Progenitor Cell Marker, Grainyhead-like 2 in 
the Developing Pituitary2 
ABSTRACT 
Background: Pituitary stem/progenitor cells give rise to all of the endocrine cell types 
within the pituitary gland and are necessary for both development and gland 
homeostasis. Recent studies have identified several key factors that characterize the 
progenitor cell population. However, little is known about the factors that regulate 
progenitor cell differentiation and maintenance. Therefore, it is crucial to identify novel 
factors that help elucidate mechanisms of progenitor cell function in the developing 
pituitary. Our studies are the first to characterize the expression of Grainyhead-like 2 
(GRHL2), a transcription factor known to regulate progenitor cell plasticity, in the 
developing pituitary. Results: Our studies show GRHL2 expression is highest in the 
embryonic and early postnatal pituitary and is localized in pituitary progenitor cells. We 
demonstrate GRHL2 expression is changed in Notch2 cKO and Prop1 df/df mice, mouse 
models that display progenitor cell number defects. In addition, our studies indicate a 
potential relationship between Notch signaling and GRHL2 expression in the developing 
pituitary. Conclusions: Taken together, our results indicate GRHL2 as a novel progenitor 
cell maker in the developing pituitary that may contribute to progenitor cell function and 
maintenance.  
                                            
2 This work is published in its entirety: Edwards, W., Nantie, L. B. and Raetzman, L. T. (2016) ‘Identification of a 
novel progenitor cell marker, grainyhead-like 2 in the developing pituitary.’, Developmental dynamics. 245(11), pp. 
1097–1106. doi: 10.1002/dvdy.24439. 
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INTRODUCTION 
The pituitary gland regulates vast physiological functions such as growth, metabolism, 
stress response and reproduction by releasing hormones from endocrine cells. The 
development of these different hormone producing cell types require putative pituitary 
stem cells, referred to as progenitor cells, to interpret both intrinsic and extrinsic cues to 
regulate cell fate choice. Pituitary progenitors express proteins required for stem cell 
maintenance such as HMG box transcription factors SOX2 and SOX9 and remain highly 
proliferative during embryonic and postnatal pituitary development (Fauquier et al., 
2008; Rizzoti et al., 2013). Recent studies have demonstrated that these cells are 
capable of differentiating into all of the endocrine cells of the pituitary during embryonic 
and postnatal development (Andoniadou et al., 2013; Fauquier et al., 2008). In addition, 
it has been demonstrated that pituitary progenitor cells in adult mice are capable of 
differentiating into endocrine cells when challenged with physiological demands such as 
target organ ablation (Nolan et al., 2004; Rizzoti et al., 2013). These studies 
demonstrate that the progenitor cell population functions as the precursor cells to each 
of the six distinct endocrine cells of the pituitary gland. However, the regulatory factors 
that influence progenitor cell maintenance and differentiation during development 
remain elusive. It is therefore important to identify novel molecules within the progenitor 
cell niche that may contribute to progenitor cell function.  
The Notch signaling pathway is associated with progenitor maintenance in many organs 
including the developing pituitary. Notch signaling it most often thought to exert self-
renewal processes in progenitor cells through transcriptional activation of its 
downstream canonical targets Hes1 and Hey1, which have been shown to 
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transcriptionally repress pro-differentiation genes (Ishibashi et al., 1994; Ishibashi et al., 
1995; Madsen et al., 2000; Weber et al., 2014). In addition, Notch has been shown to 
directly regulate the expression of genes essential for progenitor maintenance and 
function such as Sox2 and Sox9 (Li et al., 2012). Several Notch signaling genes 
including, Notch2, Notch3, Dll1, Hes1 and Hey1 are expressed in Rathke’s Pouch, in 
progenitor cells lining the marginal zone during postnatal development and the in adult 
pituitary. Manipulation of the Notch signaling pathway through genetic mouse models 
has demonstrated the importance of Notch signaling in maintaining progenitor cell 
population and cell fate selection in the developing pituitary (Nantie et al., 2014; 
Raetzman et al., 2004; Raetzman et al., 2007; Zhu et al., 2006). Studies from our lab 
have shown that Notch2 conditional knockout (cKO) mice display a misplacement and 
progressive loss of the progenitor cell population as well as decreased proliferation 
during postnatal pituitary development (Nantie et al., 2014). These data demonstrate 
that Notch signaling is essential for maintaining the correct number of progenitor cells in 
the pituitary. In addition, the Notch2 cKO mice can be used as a model for decreased 
progenitor cell number in the pituitary.  
Another important factor in controlling pituitary progenitors in both mice and humans is 
PROP1, a pituitary specific homeodomain transcription factor. The importance of 
PROP1 during pituitary development is demonstrated by the fact that mutations in 
PROP1 are the most identified cause of combined pituitary hormone deficiency (CPHD), 
accounting for approximately 50% of familial cases (Cogan et al., 1998; Ward et al., 
2005). In Ames dwarf mouse (Prop1df/df) pituitaries, a hypomorphic mutation of Prop1 
leads to an inability of progenitor cells to migrate from the periluminal zone. This results 
 
 
52 
 
in an abundance of progenitors during early gland development at the expense of 
differentiated cells of the PIT1 lineage: somatotropes, lactotropes and thyrotropes 
(Pérez Millán et al., 2016; Ward et al., 2005; Ward et al., 2006). The expansion of the 
progenitor cells is correlated with an increase in the Notch target Hey1 (Mortensen et 
al., 2011). Interestingly, in both the RBPJ and Notch2 conditional knockout models, 
reduced Notch signaling results in decreased Prop1 expression (Nantie et al., 2014; 
Zhu et al., 2006). These data indicate that Notch signaling and PROP1 both control 
progenitor maintenance and cell specification but do so through distinct mechanisms. 
Taken together, these studies indicate a major role for Notch signaling and PROP1 in 
coordinating pituitary progenitor cell fate, suggesting that they would be useful models 
to identify factors important in progenitor cells.  
In the current study, we have used the models discussed above to identify the 
transcription factor Grainyhead-like 2 (GRHL2) as a novel progenitor cell marker in the 
developing pituitary. While our studies are the first to characterize GRHL2 expression in 
pituitary gland development, in other tissues it has been identified as a marker of 
epithelial progenitor cells where it has been shown to regulate cellular proliferation, 
differentiation and migration (Chen et al., 2010; Chen et al., 2016; Gao et al., 2015; 
Varma et al., 2012). Of particular interest, studies have demonstrated increased 
expression of GRHL2 resulted in increased proliferation, blockade of differentiation and 
increased cellular life span of human keratinocytes (Chen et al., 2012). In addition, 
GRHL2 has been shown to play a crucial role in embryonic development demonstrated 
by the fact that Grhl2-null mice and N-ethyl-N-nitrosourea (ENU) induced Grhl2 mutant 
mice die embryonically due to defects in neural tube closure (Pyrgaki et al., 2011; Werth 
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et al., 2010). In particular, these defects in tissue development in Grhl2-deficient mice 
are suggested to be a result of decreased expression of cellular adhesion molecules 
such as E-cadherin (E-cad) and Claudin 4 (CLDN4), both of which have been shown to 
be direct transcriptional targets of GRHL2 (Aue et al., 2015; Werth et al., 2010). Due to 
its ability to regulate cellular processes such as cell-to-cell interactions, cell junctions 
and replicative potential, all of which are known to affect progenitor cell maintenance, 
we sought to characterize GRHL2 expression in the pituitary. Our studies demonstrate 
that GRHL2 expression is most robust in the embryonic and early postnatal pituitary and 
is predominately localized to pituitary progenitor cells. Our studies also show a 
significant decrease in Grhl2 expression in Notch2 cKO pituitaries and after chemical 
inhibition of Notch signaling via treatment. In addition, Grhl2 expression is increased in 
Prop1 mutants at a time when the Notch target Hey1 is increased. These studies are 
the first to characterize GRHL2 as a progenitor cell marker in the developing pituitary 
and correlate its expression with Notch signaling.  
MATERIALS AND METHODS 
Mice 
For GRHL2 protein analysis, wildtype mice of mixed genetic background were used. 
CD-1 mice (Charles River) from a breeding colony maintained in our lab were used for 
the Grhl2 mRNA analysis and the in vivo and vitro DAPT treatment studies.  
Notch2 cKO mice were generated as previously described (Nantie et al., 2014). Briefly, 
Notch2fl/fl mice, obtained from Jackson Laboratory (Bar Harbor) were bred to Foxg1+/cre, 
also obtained from Jackson Laboratory. Notch2+/fl; Foxg1+/cre and Notch2+/fl; Foxg1+/+ 
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littermates were then used to generate cKO animals. For genotyping, tail biopsies were 
obtained, and DNA was extracted via HotSHOT (Truett et al., 2000). Genotyping for Cre 
and Notch2 alleles was determined by PCR using as previously described using 
published primers (Hébert and McConnell, 2000; McCright et al., 2006).  
Ames Prop1+/df mice on the C57BL/6J background, provided by Dr. Sally Camper 
(University of Michigan, Ann Arbor, Michigan), were bred together to generate Prop1+/+ 
and Prop1df/df mice. For genotyping, tail biopsies were obtained, and DNA was extracted 
via salt-out method. Genotyping PCR for Prop1df mutant allele was performed as 
previously described using published primers (Himes and Raetzman, 2009).  
DAPT injections 
CD1 mice were injected starting at p2, daily for 3 days with 100 mg/kg DAPT (N-[N-(3,5-
Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester, Gamma Secretase Inhibitor 
IX (Millipore, Billerica) diluted in Dimethyl Sulfoxide (DMSO, Sigma-Aldrich) or DMSO 
alone. Pituitaries were collected 24 hours after last injection.  
Pituitary Explant Culture and DAPT Washout  
p3 pituitaries were dissected from CD-1 mice and cultured in a 96 well plate. Culture 
media consists of DMEM/F-12 media (Cellgro) supplemented with 10% fetal bovine 
serum (Hyclone) and 1% Penicillin Streptomycin (Fisher). For DAPT treatment, 10μM 
DAPT in DMSO or an equal amount of DMSO was added to cell culture media at the 
start of the culture. After 24 hours, media was spiked with DAPT or DMSO and 
pituitaries remained in culture for an additional 24 hours. For the washout assay, after 
48 hours in culture, medium was removed, pituitaries were rinsed and media containing 
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either, DMSO or 10μM DAPT dissolved in DMSO was added. Pituitaries were harvested 
after 6 hours.  
Immunohistochemistry  
Processing of pituitaries for the immunohistological analysis at e14.5, e16.5, p1 and p5, 
in Notch2 cKO mice and in Ames Dwarf mice was performed as previously described 
(Nantie et al., 2014). Briefly, whole e14.5 and e16.5 embryos and heads of postnatal 
mice were fixed in 3.7% formaldehyde and embedded in paraffin for sectioning. 
Samples were deparaffinized, rehydrated and boiled in a 10 mM citrate solution. Anti-
GRHL2 antibody was purchased from Sigma Aldrich and was previously validated by 
the Human Protein Atlas (HPA) project (Uhlén et al., 2015). For Immunohistological 
detection of GRHL2 (1:500-1:1000) tyramide signal amplification was used (TSA) 
(Perkin Elmer) and slides were blocked with TNB blocking solution containing 0.1 M 
Tris–HCl, 0.15 M NaCl, and 0.5% TSA Blocking Reagent diluted in sterile ddH2O (pH 
7.5). Slides were incubated with biotin-conjugated rabbit secondary antibody (1:200; 
Jackson ImmunoResearch) diluted in the TNB blocking solution. This was followed by 
incubation with streptavidin-HRP (1:100) and incubation with Cyanine-3 within the TSA 
Kit (Perkin Elmer) according to the manufacturer’s protocol. For p30 animals, pituitaries 
were fixed in 3.7% formaldehyde, cyroprotected in a 30% sucrose/PBS solution, then 
frozen in Optimal Cutting Temperature compound (Electron Microscopy Sciences). 
Frozen sections were thawed for 10 minutes, then fixed with 3.7% formaldehyde. 
Immunohistological detection of GRHL2 was performed using TSA as described above.  
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For double-stains, p1 heads were fixed using a Zinc fixative (BD Pharmigen). Slides 
were first stained with GRHL2 using TSA as described above. Slides were then blocked 
with a blocking solution (3% bovine serum albumin (Jackson ImmunoResearch) and 
0.5% Triton X-100 (Sigma Aldrich) diluted in PBS), 1% Peroxidase-conjugated 
streptavidin (Jackson ImmunoResearch) and 1% Donkey Anti-Rabbit IgG (Jackson 
ImmunoResearch). Following incubation with the blocking solution, slides were 
incubated with the following primary antibodies, SOX2 (1:1000; Millipore), PIT1 (1:1000; 
kind gift of Dr. Simon Rhodes), adrenocorticotropic hormone (ACTH) (1:100; DAKO), 
LHβ (1:100; Dr. A. F. Parlow and the National Hormone and Pituitary Program, 
University of California, Los Angeles), PCNA (1:200; Cell Signaling), and E-cadherin 
(1:100; Cell Signaling). These antibodies were diluted in the blocking solution described 
previously. Slides were then incubated with either biotin-conjugated rabbit secondary 
antibody (SOX2, Pit1, POMC, LHβ and E-cadherin) or biotin-conjugated mouse 
secondary antibody (PCNA) (1:200; Jackson ImmunoResearch). This was followed by 
incubation with streptavidin-conjugated Cy2 fluorophore (1:200; Jackson 
ImmunoResearch). As a control, slides without each primary antibody were included for 
each experiment to ensure staining specificity. All slides were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) (1:1000; Life Technologies).  Slides were visualized at 
200x and 400x with a Leica DM2560 microscope or at 630x using a using a Leica 
DMI4000B confocal microscope and processed as previously described (Nantie et al., 
2014).  
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Quantitative RT-PCR (qRT-PCR) 
RNA was processed as previously described (Nantie et al., 2014). Briefly, an 
RNAqueous micro kit (Ambion) was used to isolate RNA from individual pituitaries and 
total amount of RNA obtained from each pituitary was converted to cDNA with 
ProtoScript M-Mulv First Strand cDNA Synthesis Kit (New England Biolabs).  For adults, 
0.5ug of RNA was converted to cDNA. The following primer sequences were used; 
Grhl2 forward: GAA AGC CAC AAA GCA TCA GGA C, Grhl2 reverse: AGA CAG CAC 
AGC GAC ATG GAAG. Gapdh levels were used to normalized data, using the following 
primers; Gapdh forward: GGT GAG GCC GGT GCT GAG TAT G, Gapdh Reverse: 
GAC CCG TTT GGC TCC ACC CTT C. The standard comparative Δcycle threshold 
value method was used for data analysis as previously described (Goldberg et al., 
2011). Statistical significance was determined by Student’s t test.  
RESULTS 
Characterization of GRHL2 in the embryonic, postnatal and adult pituitary.  
Expression of GRHL2 in the developing mouse pituitary has yet to be characterized. 
Therefore, we examined the spatial and temporal expression patterns of GRHL2 in the 
embryonic, postnatal and adult pituitary. At e12.5 and e14.5, the vast majority of cells in 
Rathke’s pouch are GRHL2-immunopositive (Figure 3.1A and 3.1B). By postnatal day 1 
(p1) GRHL2 expression is restricted to the marginal cells lining the lumen with a few 
positive cells scattered in the dorsal intermediate lobe (IL) and anterior lobe (AL) 
parenchyma (Figure 3.1C). At p5 there is a decrease in GRHL2 expression, with the 
most apparent reduction in the cleft cells of the intermediate lobe (IL) (Figure 3.1D). At 
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p30, GRHL2 expression is maintained in the cleft cells but overall expression is reduced 
compared to the embryonic and postnatal pituitary (Figure 3.1E). In addition, we used 
qRT-PCR to determine relative mRNA levels of Grhl2 at e16.5, p1, p5, p10, and p21, 
compared to adult pituitaries. These data parallel the protein analysis of GRHL2 
expression in that it shows Grhl2 mRNA is expressed throughout pituitary gland 
development. In addition, these data indicate that Grhl2 expression is highest during the 
early postnatal time period with a peak at p1, compared to adult pituitaries (Figure 
3.1F). Taken together, these data show GRHL2 is maintained throughout pituitary 
maturation and appears to peak during postnatal development.  
GRHL2 is predominantly present in the non-hormone producing cells of the developing 
pituitary. 
The localization of GRHL2 in cells that line the lumen of anterior (AL) and intermediate 
lobe (IL) of the pituitary strongly suggests GRHL2 is present in the progenitor cell 
population. However, GRHL2 is also expressed in the AL parenchyma and in cells 
outside of the marginal zone of the IL (Figure 3.2A, 3.2D, 3.2G, 3.2J, 3.2M, 3.2P and 
3.2S). These areas of the pituitary have been shown to contain a small number of 
progenitors but are predominately populated with differentiated endocrine cells. We 
used immunohistochemistry to determine if GRHL2 is expressed in both the progenitor 
and hormone producing cells in the AL and IL at p1. SOX2, a progenitor cell maker, is 
expressed predominantly in the cleft cells surrounding the lumen and in a few scatted 
cells within the anterior lobe parenchyma (Figure 3.2B, 3.2E and 3.2H). GRHL2 
expression is detected in nearly all of the SOX2 positive cells of both the AL and IL 
(Figure 3.2C, 3.2F and 3.2I). POMC is expressed in corticotrope cells in the AL and in 
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melanotropes in the IL (Figure 3.2K and 3.2N, respectively). GRHL2 does not appear to 
be expressed in corticotrope cells (Figure 2L). In the IL, cells that have high expression 
of GRHL2 did not co-express POMC (Figure 3.2O and 3.2O’). However, we did observe 
colocalization of GRHL2 and POMC in small number of cells that weakly express 
GRHL2 (Figure 3.2O’’, arrows). To determine if GRHL2 expression was detected in 
somatotropes, thyrotropes and lactotropes we used immunohistochemistry of PIT1, a 
transcription factor that is necessary for the differentiation of each of these cell types 
(Figure 3.2Q). In cells that show a strong expression of GRHL2 we did not observe 
colocalization with PIT1. In contrast, we did observe colocalization of GRHL2 and PIT1 
in cells that appeared to have reduced but not absent expression of GRHL2 (Figure 
3.2R, arrows). Expression of GRHL2 in gonadotrope cells was determined by 
colocalization with luteinizing hormone (LHβ) (Figure 3.2T). The vast majority of GRHL2 
positive cells were not found to be LHβ positive however, a doubled labeled cell was 
occasionally detected (Figure 3.2U, arrows). Taken together, these data indicate that 
GRHL2 is predominately expressed in the progenitor cell population in the developing 
pituitary. 
GRHL2 expression is increased in the Ames Dwarf (Prop1df/df) postnatal pituitary.  
To further demonstrate that GRHL2 correlates with the presence of the progenitor cell 
population we examined its expression in Ames dwarf (Prop1df/df) mouse postnatal 
pituitaries by immunohistochemistry and qRT-PCR. Prop1df/df mice show an expansion 
of the luminal pituitary progenitor cell population due to an inhibition of these cells to 
differentiate into the endocrine cell types (Pérez Millán et al., 2016; Ward et al., 2005; 
Ward et al., 2006). We therefore used this mouse as a model for increased pituitary 
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progenitor cell number.  In control mice at p5, GRHL2 expression is present in the 
luminal cells of the anterior and intermediate lobes with a few cells scattered in the 
anterior lobe parenchyma (Figure 3.3A and 3.3C).  A similar pattern of localization is 
detected in the Ames dwarf mouse pituitary. In addition, the number of GRHL2 positive 
cells surrounding the AL lumen appears to increase in Ames dwarf mice (Figure 3.3B 
and 3.3D). Coincidentally, we observe a significant increase in Grhl2 mRNA expression 
in Ames dwarf mice compared to controls (Figure 3.3E). These findings show GRHL2 
protein and mRNA expression correlates with progenitor cell number in the developing 
pituitary.  
GRHL2 expression is reduced in the Notch2 cKO mice. 
In contrast to Ames dwarf mice, the progenitor cell population is progressively lost in 
Notch2 cKO mice. Therefore, we sought to examine changes in GRHL2 expression in 
this model of decreased progenitor cell number. In control mice at p1, GRHL2 
expression is robustly expressed in cleft cells of both the AL and IL and is present in a 
few scattered cells in the AL parenchyma (Figure 3.4A, 3.4B, and 3.4C).  In contrast, 
GRHL2 expression appears to be significantly decreased in cells lining the marginal 
zone of Notch2 cKO mice (Figure 3.4D). Notably, the cleft cells of the intermediate lobe 
appear to have the most marked reduction in GRHL2 expression (Figure 3.4E) while the 
AL cleft cells appear to be unaffected (Figure 3.4F).  These findings are further 
supported by the significant decrease in Grhl2 mRNA levels in the Notch2 cKO mice 
compared to controls at p1 (Figure 3.4G). These data indicate that loss of progenitor 
cells in the Notch2 cKO mice results in decreased expression of GRHL2 during early 
postnatal development.  
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Postnatal Notch inhibition results in decreased Grhl2 expression.  
Loss of GRHL2 in Notch2 cKO may simply be due to a reduction in progenitor cell 
numbers. However, this observation may indicate that Grhl2 expression is regulated by 
Notch signaling. To determine if an acute reduction in Notch signaling during the 
postnatal period was sufficient to decrease Grhl2 expression, mice were injected with N- 
[N-(3,5- difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT), a gamma 
secretase inhibitor that blocks Notch signaling, during the early postnatal period 
following the dosing paradigm in Figure 3.5A. A significant reduction in Grhl2 mRNA 
levels was observed in mice dosed with DAPT compared to vehicle-treated controls, 
suggesting Grhl2 as a Notch regulated gene (Figure 3.5B). To determine if the potential 
regulation of Grhl2 by Notch signaling is direct or indirect, we used an explant culture 
system to examine effects of DAPT treatment at the level of the pituitary. Pituitaries 
were treated as depicted in Figure 3.5C. Quantifications of Grhl2 mRNA levels in each 
of the conditions show Grhl2 mRNA levels are reduced after DAPT treatment and 
recover to control levels after 6 hours of DAPT washout (Figure 3.5D). These data 
suggest that the decrease in Grhl2 we observe in the Notch2 cKO mice is due to 
inherent changes at the level of the pituitary. Furthermore, the increase in Grhl2 mRNA 
levels within 6 hours of DAPT removal further suggests Grhl2 as a potential direct Notch 
target, as this same pattern is observed with Hes1, Hey1 and Prop1 (Nantie et al., 
2014).  
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Downstream Targets of GRHL2, E-cadherin and PCNA are decreased in the Notch2 
cKO mice.  
It is well established in other tissues that GRHL2 is a suppressor of epithelial 
differentiation (Chen et al., 2012; Tanimizu et al., 2014b). GRHL2 controls this process 
by directly regulating the expression of genes necessary for maintaining cellular 
proliferative capacity. Included in the GRHL2 regulatory network are genes responsible 
for cellular adhesion such as E-Cadherin (E-cad), as well as genes that direct cellular 
proliferation such as Proliferating Cell Nuclear Antigen (PCNA) (Chen et al., 2010; 
Werth et al., 2010). We therefore sought to characterize expression of these 
downstream targets in the postnatal pituitary by immunohistochemistry. Furthermore, 
because we observe a reduction of GRHL2 expression in Notch2 cKO mice pituitaries 
we analyzed E-cad and PCNA expression in these mice. In control mice, E-cad is highly 
expressed in both the intermediate and anterior lobes of the developing pituitary (Figure 
3.6A, 3.6C and 3.6E). GRHL2 strongly colocalizes in cells that express E-cad, which is 
most apparent in the luminal cells of both IL and AL. However, we did observe cells that 
expressed E-cad but did not appear to be GRHL2 positive (Figure 3.6B, 3.6D and 3.6F). 
In Notch2 cKO pituitaries, we observe a dramatic reduction in E-cad expression 
specifically in the IL with only a few positive cells remaining (Figure 3.6G and 3.6I). 
Interestingly, the few cells that maintain E-cad expression in the IL also express GRHL2 
(Figure 3.6H and 3.6J). In contrast, the expression of E-cadherin and GRHL2 appear to 
be relatively unaffected in anterior lobe of cKO pituitaries (Figure 3.6K and 3.6L). 
 In control mice, PCNA expression closely mimics that of other cell proliferation markers 
such as Ki67, with concentrated expression in the luminal cells and appreciable levels 
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throughout the AL and IL (Figure 3.7A, 3.7C and 3.7E). As expected, PCNA colocalizes 
with GRHL2 expressing cells particularly in luminal cells of both the AL and IL, where 
we almost never observed a GRHL2 positive cell that was not also positive for PCNA 
(Figure 3.7B, 3.7D and 3.7F). In cKO mice, there appears to be a reduction in PCNA 
expression specifically in IL cleft cells where we detect very few PCNA-positive cells 
(Figure 3.7G and 3.7I). Although PCNA and GRHL2 expression is drastically reduced in 
the IL cleft, a small number of positive cells remain in the dorsal IL that co-express 
PCNA and GRHL2 (Figure 3.7H and 3.7J). No obvious changes in expression of PCNA 
are detected in the AL marginal cells of Notch2 cKO mice compared to control (Figure 
3.7K). Conversely, colocalization of GRHL2 and PCNA appears to be unaffected in the 
AL (Figure 3.7L).  Taken together, these data indicate known GRHL2 targets E-cad and 
PCNA are highly expressed in the postnatal pituitary. In addition, we demonstrate that 
these targets are reduced in the Notch2 cKO mice pituitaries suggesting that the loss of 
Notch and subsequent loss of GRHL2 expression correlates with changes in these 
downstream genes.  
DISCUSSION 
The stem/progenitor cell population of the pituitary gland has been identified as the 
precursor cells that give rise to all of the hormone producing cell types. This cell 
population is necessary for embryonic and postnatal expansion of the gland and also 
plays a critical role in the physiological response of the adult. While recent advances 
have been made in identifying these cells relatively little is known about the factors that 
regulate the progenitor cell niche in the developing pituitary. Our studies characterize 
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the expression of GRHL2 in the pituitary and identify this transcription factor as a novel 
pituitary progenitor cell marker.  
The pituitary progenitor cells are characterized by the expression of hallmark stem cell 
factors such as the high-mobility group (HMG) box transcription factor, SOX2. Recent 
studies, both in vitro and in vivo studies have demonstrated that SOX2 expressing 
progenitors differentiate into all of the different endocrine cell types of the anterior 
pituitary (Fauquier et al., 2008). Additional factors have also been identified as 
progenitor cell markers, including SOX9, OCT4, GRFa2, S100 and PROP1 (Chen et al., 
2005; Fauquier et al., 2008; Garcia-Lavandeira et al., 2009; Yoshida et al., 2009). 
Interestingly, these factors are not ubiquitously expressed in all pituitary progenitors, 
indicating a heterogeneous population of progenitor cells whose functional differences 
have yet to be elucidated. More recently, in vivo studies have shown that PROP1 
expressing cells also have the ability to differentiate into all of the hormone-producing 
cells types of the anterior pituitary (Davis et al., 2016). These studies demonstrate that 
SOX2 and PROP1 expressing progenitors serve as the precursor cells to the 
differentiated pituitary cell types, however loss of function studies for both of these 
factors does not eliminate differentiation of all the pituitary lineages (Jayakody et al., 
2012; Ward et al., 2005; Ward et al., 2006). Taken together, these studies indicate that 
other pituitary progenitor factors must play a role in pituitary development. Therefore, 
identification of novel progenitor cell markers such as GRHL2 will provide new insight 
into the regulation and maintenance of pituitary progenitor cells.  
GRHL2 expression marks the progenitor cell population in the developing pituitary. The 
spatial and temporal pattern of GRHL2 in the pituitary closely mimics the expression 
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pattern of other progenitor cell markers including SOX2, SOX9, Notch2 and Prop1 
(Garcia-Lavandeira et al., 2009; Nantie et al., 2014; Ward et al., 2005; Yoshida et al., 
2011). In agreement with this observation, we show that GRHL2 is expressed almost 
exclusively in SOX2 positive cells and is either absent or minimally detected in the 
majority of the endocrine cell types of the anterior pituitary. This finding is consistent 
with localization patterns of GRHL2 in other tissues including the liver, where GRHL2 is 
detected in epithelial cells that express stemness markers such as SOX9 (Tanimizu et 
al., 2013). Interestingly, at e14.5 GRHL2 can be detected in both Rathke’s Pouch (RP) 
and in the anterior lobe (AL). At this period in development, the AL contains 
differentiated cell types and a large number of cells that have been designated as non-
cycling precursor cells that are thought to be transitioning into fully differentiated 
endocrine cell types (Bilodeau et al., 2009).  A similar phenomenon can be seen during 
postnatal pituitary development in which we observe a low level of GRHL2 expression in 
cells directly outside of the progenitor cell niche that are positive for lineage commitment 
makers such as PIT1. A subset of PIT1 positive cells also express the progenitor cell 
marker PROP1 and are also suggested to be cells transitioning from a progenitor cell 
state to terminally differentiated cell (Yoshida et al., 2009; Yoshida et al., 2013). In 
addition, it has been shown that a population of terminally differentiated cells are mitotic 
during postnatal pituitary expansion (Carbajo-Perez and Watanabe, 1990; Taniguchi et 
al., 2002). Therefore, cells that co-express both GRHL2 and terminal differentiation 
makers, as was observed in a minority of melanotropes and gonadotropes, could 
possibly be indicative of differentiated cells that display mitotic activity. Together, these 
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observations indicate that GRHL2 expression may mark both a progenitor cell 
population and transitional cells. 
We further demonstrate GRHL2 as a progenitor cell marker by correlating its expression 
with changes in progenitor cell number in the Prop1df/df and Notch2 cKO pituitaries. 
PROP1, a pituitary specific transcription factor expressed in pituitary progenitor cells, 
coordinates endocrine cell differentiation by regulating the expression of PIT1, which is 
necessary for expression of GH, PRL, and TSHβ.  Prop1df/df mice have an expansion of 
progenitor cells in the marginal zone (MZ) of the pituitary due to a failure of epithelial to 
mesenchymal transition and the subsequent inability of these cells to further 
differentiate (Pérez Millán et al., 2016; Ward et al., 2006). Therefore, we used Prop1df/df 
mice as a model for progenitor cell increase during early pituitary development.  We 
show that expression of GRHL2 is significantly increased in the MZ of Prop1df/df 
pituitaries at postnatal day 5 (p5), indicating that an increase in progenitor cell number is 
associated with an increase in GRHL2 expression. In contrast, the loss of Notch2 during 
pituitary development is associated with a decrease in the progenitor cell pool. 
Therefore, this model was used to examine changes in GRHL2 expression in pituitaries 
with a decreased number of progenitor cells.  We show that loss of Notch2 results in 
decreased expression of GRHL2 at p1. In particular, the most drastic reduction in 
GRHL2 expression was seen in IL progenitor cells. Similar observations were reported 
for other progenitor cell markers SOX2 and SOX9 in Notch2 cKO mice (Nantie et al., 
2014).  Taken together, these data demonstrate that modulations in the progenitor cell 
population can be detected by the changes in GRHL2 expression.  
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It can be postulated that the reduction in GRHL2 expression in the Notch2 cKO is solely 
a consequence of progenitor cell loss. Alternatively, this reduction could imply Notch 
signaling as novel regulator of GRHL2 expression in the developing pituitary. We 
therefore sought to assess if Grhl2 could be regulated by Notch. Our data shows that 
pituitaries exposed acutely in vivo and in vitro to DAPT, a gamma secretase inhibitor, 
display a significant reduction in mRNA levels of Grhl2. These data have several 
implications about Notch regulation of Grhl2 expression. First, this suggests that the 
decrease is GRHL2 expression we observe in the Notch2 cKO mice is not merely a 
consequence of the long-term loss of Notch. In addition, our in vitro data implies that the 
reduction of Grhl2 in Notch2 cKO mice is a direct effect on the pituitary and not due to 
extrinsic factors. Furthermore, in vitro Grhl2 mRNA levels recover after 6 hours of DAPT 
washout, a pattern that is observed with direct downstream Notch targets including 
Hes1 and Hey1 (Chadwick et al., 2009; Nantie et al., 2014; Weng et al., 2006). 
Therefore, these data may suggest that Grhl2 is directly regulated by Notch signaling. 
GRHL2 has not been previously been shown to be regulated by Notch signaling in 
mammalian cells. However, a recent study demonstrated the drosophila homologue, 
Grainyhead (Grh) is directly regulated by Notch signaling in neuroblasts (Zacharioudaki 
et al., 2016). Furthermore, studies in other mammalian tissues have eluded to a 
potential relationship between Notch signaling and GRHL2 expression. For example, 
several studies have demonstrated that active Notch signaling promotes the 
differentiation of cholangiocytes from hepatoblasts during liver development (Tanimizu 
and Miyajima, 2004; Wang et al., 2014). Interestingly, GRHL2 in addition to other well-
established Notch targets including Hes1, Hey1, and Sox9 were identified as 
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cholangiocyte specific markers (Tanimizu et al., 2014a), suggesting Notch regulation of 
GRHL2 occurs in the liver. In addition, in lung epithelium GRHL2 has been suggested to 
regulate expression of Notch3 and Notch1 (Gao et al., 2015). This may indicate that 
there is a reciprocal relationship between Notch and GRHL2 regulation. However, 
further studies are necessary to determine if Grhl2 is in fact a direct Notch target in the 
pituitary. 
Another link between the Notch signaling pathway and GRHL2 is that they appear to 
regulate many of the same cellular pathways. Both Notch and GRHL2 are thought to be 
important in stem cell maintenance and regulation of differentiation. A potential 
relationship between the two has been established in drosophila studies, identifying that 
GRH works in synergy with Notch to regulate target-gene expression (Furriols et al., 
2001). In support of this observation, a recent study identified GRHL2 and the essential 
Notch co-activator protein, RBPJ, as a part of the OCT4 interactome, a transcription 
factor critical for the maintenance of stem cell pluripotency. These studies indicate a 
large number of transcription factors work in concert to regulate cellular plasticity and 
self-renewal (van den Berg et al., 2010). This implies that GRHL2 and Notch may work 
synergistically to regulate genes necessary for progenitor cell maintenance in the 
pituitary.   
While the function of GRHL2 in the pituitary has yet to be elucidated, its function is well 
established in other tissues. GRHL2 has been shown to regulate genes that are 
important in maintaining epithelial integrity and regulation of cellular differentiation. In 
particular, GRHL2 is a direct transcriptional regulator of Cdh1 (E-cadherin), a cellular 
adhesion molecule, during embryonic development and in epithelial cells of several 
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different tissues including the liver, lung and gut (Varma et al., 2012; Werth et al., 2010). 
In human keratinocytes, GRHL2 also been shown to directly regulate the expression of 
cellular proliferation proteins such as Ki67 and PCNA (Chen et al., 2010; Chen et al., 
2012). Our studies demonstrate that GRHL2 expression is strongly associated with both 
E-cadherin and PCNA expression in the postnatal pituitary. In addition, Notch2 cKO 
mice show a drastic reduction in E-cadherin and PCNA expression in the in the cleft 
cells of the IL, a region in which GRHL2 expression is also reduced. The bias of IL 
expression disruption correlates with selective stem cell marker loss in the IL of Notch2 
cKO mice at the same age (Nantie et al., 2014). These data may indicate that GRHL2 
functions to regulate cellular proliferation and cellular adhesion in the developing 
pituitary. Furthermore, E-cadherin expression is also important for stem cell adhesion 
and is a necessary factor for the maintenance of the stem-cell niche in other tissues 
(Chen et al., 2013). Therefore, it could be postulated that expression of GRHL2 is 
important in the maintenance of the progenitor cell niche in the developing pituitary. 
However, the reduced expression of known GRHL2 targets we observe in Notch2 cKO 
mice could be due to expression changes in other regulators of these genes. Notch 
signaling directly regulates transcription of cell cycle genes including Ccnd1, Ccnd3 and 
Cdnk1 (Cohen et al., 2010; Georgia et al., 2006; Joshi et al., 2009). Therefore, the 
decrease in the cellular proliferation genes in Notch2 cKO mice could be a direct 
consequence of reduced Notch signaling. While our data provided evidence to a 
potential function of GRHL2 in the pituitary, future studies are necessary to elucidate the 
role of GRHL2 in the developing pituitary. 
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FIGURES 
Figure 3.1: GRHL2 is expressed in the embryonic, postnatal and adult pituitary. GRHL2 
is expressed throughout the pituitary at e12.5 (A) and is highly expressed in the cells 
lining the cleft as well as the intermediate (IL) and anterior lobe (AL) of the pituitary at 
e12.5 (A), e14.5 (B) and p1 (C). GRHL2 expression appears to be reduced at p5 (D). 
GRHL2 expression persists in the IL and AL lobes of p30 pituitaries.  Grhl2 mRNA is 
detected in the embryonic, postnatal and in adult pituitaries. Ghrl2 expression peaks at 
p1 when compared to adult levels (F). Scale bar = 50 μm. n=3-4 
(immunohistochemistry). n=3-4 (qRT-PCR). 
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Figure 3.2: GRHL2 is predominantly expressed in progenitor cells in the postnatal 
pituitary. At p1 GRHL2 positive cells are mostly restricted to the intermediate lobe (IL) 
(A and M) and anterior lobe (AL) cleft cells (D and S) and a few GRHL2 positive cells 
are detected in the AL parenchyma (G, J and P). SOX2 is expressed in the cleft cells of 
the IL (B) and AL (E) cells of wild type pituitaries. A few SOX2 positive cells are 
detected in the AL parenchyma (H). GRHL2 is detected in the vast majority of SOX2 
positive cells in both the IL (C) and AL (F and I). POMC is expressed in the AL 
parenchyma (K). GRHL2 expression is absent from POMC positive cells in the AL 
parenchyma (L). POMC is also expressed in dorsal IL (N). The majority of cells that 
express GRHL2 in the IL are not POMC positive (O and O’).  A small subset of POMC 
positive cells appear to weakly express GRHL2 in the dorsal IL (O’’, arrows). PIT1 is 
highly expressed in the anterior lobe parenchyma (Q).  GRHL2 is absent from the 
majority of PIT1 positive cells but was detected in a small population of cells that weakly 
express GRHL2 (R). LH positive cells are confined to the AL parenchyma (T). 
Occasionally, cells double-labeled with GRHL2 and LH were detected in the AL but the 
majority of LH positive cells do not co-express GRHL2 (U). Arrows indicate double-
labeled cells. Scale bar = 50 μm (A-U). Scale bar = 5 μm (O’ and O’’). n=3-4.  
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Figure 3.3: GRHL2 expression is increased in Prop1df/df mice at p5. GRHL2 expression is mainly detected in the cleft cells 
of the anterior lobe (AL) and intermediate lobe (IL) cells of control pituitaries (A and C). In Prop1df/df pituitaries, the number 
of GRHL2 positive cells appears to be increased in the AL cleft (B and D).  Grhl2 mRNA levels are significantly increased 
in Prop1df/df mice pituitaries compared to controls (E). *, P < 0.05. n=3 (immunohistochemistry). n=3-4 (qRT-PCR). 
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Figure 3.4: Loss of Notch2 results in decreased expression of GRHL2 in p1 pituitaries. GRHL2 is expressed in the anterior 
(AL) and intermediate (IL) lobe cleft cells and in cells scattered throughout the AL parenchyma of control pituitaries (A). 
Boxed region of IL is shown in (B) and AL in (C). In the Notch2 cKO mice, GRHL2 expression is drastically decreased in 
the cleft cells of the IL (D, boxed region shown in E). GRHL2 expression appears to be unaffected in anterior lobe cells (D, 
boxed region shown in F). A significant decrease in mRNA levels of Grhl2 is observed in the Notch2 cKO pituitaries 
compared to controls. *, P < 0.05. Scale bar = 50 μm. n=3 (immunohistochemistry). n=7 (qRT-PCR). 
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Figure 3.5: Grhl2 is significantly decreased in vivo and in vitro after treatment with DAPT 
during postnatal pituitary development. Schematic representing dosing paradigm for 
mice treated with DAPT, a gamma secretase inhibitor that is known to block Notch 
signaling (A). A significant decrease is observed in Grhl2 mRNA levels after in vivo 
treatment with DAPT (B). Schematic showing paradigm for pituitary explant culture 
treatment with DAPT (C). A significant decrease is observed in Grhl2 mRNA levels after 
in vitro DAPT treatment compared to vehicle treated controls. Grhl2 mRNA levels 
recover after DAPT is removed from the culture media (D). *, P < 0.05. n= 5 to 8 (qRT-
PCR in vivo), and n= 4 to 8 (qRT-PCR in vitro).
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Figure 3.6: Notch2 cKO mice have decreased E-cadherin expression at p1. In control mice, E-cadherin expression is 
detected throughout the anterior pituitary but appears to be concentrated in the cleft cells of the intermediate lobe (IL) (A 
and C) and anterior lobe (AL) (A and E). In control mice, GRHL2 immunopositive cells appear to co-express E-cadherin in 
the pituitary cleft cells of the IL (B and D) and AL (B and F). Colocalization of E-cadherin and GRHL2 is also detected AL 
parenchyma (F). In contrast, in cKO mice, E-cadherin expression is decreased in the cleft cells of IL (G and I). 
Colocalization of E-cadherin and GRHL2 is lost in the cleft cells of IL (J). A few cells show E-cadherin and GRHL2 co-
localization in dorsal IL (H and J). Expression of E-cadherin appears unaffected in the AL (G and K). No change in 
colocalization of E-cadherin and GRHL2 is observed in the AL cleft and AL parenchyma (H and L).  Scale bar = 50 μm. 
n=3-4.  
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Figure 3.7: Notch2 cKO pituitaries have decreased PCNA expression at p1. In control animals, PCNA is detected in the 
intermediate lobe (IL) (A and C) and anterior lobe (AL) cleft cells (A and E) and in cells scattered in the dorsal IL and AL 
parenchyma (A and E).  The vast majority of PCNA immunopositive cells co-express GRHL2 in the cleft of both the IL (B 
and D) and AL (B and F). In the dorsal IL (B) and AL parenchyma (F), a large number of cells are double-labeled and 
small subset of cells that express only GRHL2 or PCNA are detected. In contrast, in cKO mice the number of PCNA 
positive cells appears to be decreased specifically in the IL cleft cells (G and I). The colocalization of PCNA and GRHL2 is 
not detected in the IL cleft cells of cKO mice (H and J). Expression of PCNA in the AL cleft and AL parenchyma appears 
unaffected (G and K). Colocalization of PCNA and GRHL2 does not appear to be changed in the AL cleft and AL 
parenchyma (H and L). Scale bar = 50 μm. n=4
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CHAPTER 4: Notch Signaling Regulates Pre-Receptor Glucocorticoid Signaling in 
the Developing Pituitary 3 
ABSTRACT 
The Notch signaling pathway is a critical regulator of cell fate determination during 
postnatal pituitary development. Notch signaling functions to promote differentiation of 
PIT1 lineage differentiation and suppress aberrant corticotrope differentiation. However, 
the mechanism by which Notch signaling regulates this developmental cell fate choice 
remains elusive. In our current study we identify 11-beta hydroxysteroid dehydrogenase 
type 1 (11β-HSD1), an enzyme that regulates intracellular levels of active 
glucocorticoids, as a novel Notch signaling target in the developing pituitary that may 
serve as a downstream regulator of corticotrope differentiation. We use genetic mouse 
models, chemical inhibition of Notch signaling and reporter gene studies to demonstrate 
Hsd11b1 is a Notch regulated gene and a potential direct transcriptional target of the 
pathway. In addition, we generated mice with a conditional deletion of Hsd11b1 in 
POMC expressing cells; these mice demonstrate that 11β-HSD1 functions to 
suppresses corticotrope gene expression in the postnatal pituitary. These data suggest 
that Notch-mediated regulation of Hsd11b1 is a novel mechanism by which the pathway 
controls corticotrope specification.   
INTRODUCTION 
The pituitary gland is a central regulator of the endocrine system and is responsible for 
the release of hormones that regulates crucial physiological functions including growth, 
                                            
3 The following are contributing authors to this work: Leah B. Nantie, Gareth G. Lavery and Lori T. Raetzman  
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metabolism, reproduction, lactation and the body’s response to stress. Pituitary gland 
development is dependent on the ability of pituitary progenitors to interpret intrinsic and 
extrinsic developmental cues to coordinate the balance of progenitor maintenance, 
proliferation, and differentiation of the endocrine cell types. During postnatal 
development of the pituitary a massive increase in pituitary size is observed, due in part 
to increased differentiation of the hormone producing cells types (Carbajo-Perez and 
Watanabe, 1990). However, the key molecular mechanisms that dictate lineage 
specification during this time period remain relatively unexplored.   
The Notch signaling pathway, an evolutionarily conserved cell-to-cell signaling pathway, 
plays a crucial role in the regulation of progenitor maintenance and differentiation during 
postnatal pituitary development. Notch signaling pathway components, including the 
Notch receptors Notch1, and Notch2, as well as the canonical downstream targets, 
Hes1 and Hey1 are detected in the postnatal pituitary and are enriched within the 
progenitor cell population (Chen et al., 2006; Nantie et al., 2014). Genetic experiments 
in mice with conditional loss of the Notch signaling components demonstrate the 
importance of this pathway in the regulation of pituitary cell fate choice. Research from 
our laboratory shows mice with a conditional loss of the Notch2 receptor (Notch2 cKO) 
display aberrant corticotrope differentiation coincident with a decrease in the PIT1 
lineage cell types, specifically during postnatal pituitary development (Nantie et al., 
2014). While these studies prove the Notch signaling pathway is an important regulator 
of binary cell fate choice in the postnatal pituitary, dictating the balance between the 
corticotrope and PIT1 lineage, the mechanism by which Notch signaling regulates these 
developmental processes in the postnatal pituitary remains elusive. 
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The Notch signaling pathway is thought to influence Pit1 lineage differentiation in part 
by directly regulating expression of Prop1, a pituitary specific transcription factor 
required for transcription of Pit1 (Nasonkin et al., 2004). In contrast, the mechanism by 
which the Notch signaling pathway suppresses corticotrope differentiation is poorly 
understood. Similar to the Notch signaling pathway, the glucocorticoid signaling 
pathway has also been shown to suppress corticotrope differentiation. It is well 
established that glucocorticoids negatively regulate the activity of the Hypothalamic-
Pituitary-Adrenal (HPA) axis by inhibiting the release and synthesis of corticotropin 
releasing hormone (CRH) from the hypothalamus and adrenocorticotropic hormone 
(ACTH) from corticotropes in the anterior pituitary. In addition, glucocorticoids also 
regulate corticotrope cell number in the pituitary such that adrenalectomy results in an 
increase in corticotrope cell number in adult mice (Nolan et al., 2004). This response is 
attenuated if mice are treated with the synthetic glucocorticoid dexamethasone 
immediately following adrenalectomy, suggesting that the loss of circulating 
glucocorticoids is responsible for the increase in cell number (Nolan and Levy, 2006; 
Nolan et al., 2004). Furthermore, mice with a conditional loss of glucocorticoid receptor 
(Nr3c1) in Pomc expressing cells (Nr3c1POMCCre) show an increase in 
proopiomelanocortin (Pomc) mRNA and an apparent increase in corticotrope cell 
number at postnatal day 6 (Schmidt et al., 2009).  These studies indicate that the 
pituitary is able to regulate corticotrope cell number in response to glucocorticoids at 
both postnatal and adult ages. We propose the Notch signaling pathway may modulate 
the glucocorticoid signaling pathway to influence corticotrope differentiation.  
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In our current studies we identify Hsd11b1, a pre-receptor regulator of glucocorticoid 
signaling, as a novel Notch regulated gene in the postnatal pituitary. 11β-HSD1 
predominantly acts as a reductase converting the inactive glucocorticoid, cortisone (11-
dehydrocorticosterone in rodents), to the active cortisol (corticosterone in rodents) in a 
tissue-specific manner.  11β-HSD1 is widely expressed including the central nervous 
system, liver, kidney, adipose tissue and lung. Ontological studies of Hsd11b1 have 
shown that its expression in most tissues is relatively undetectable until right before 
birth and increases significantly during postnatal development (Diaz et al., 1998; Maser 
et al., 1994; Yang et al., 1995). Previous studies in mice with a global loss of Hsd11b1 
demonstrate its role in metabolic syndrome, immune function, as well as activity of the 
HPA axis (Carter et al., 2009; Harris et al., 2001; Hennebold et al., 1997; Morton, 2010; 
Thieringer et al., 2001). Based on these observations we hypothesize that Notch 
signaling may regulate Hsd11b1 in order to amplify intracellular levels of glucocorticoids 
that in turn would function to suppress corticotrope expansion.  
Using mice with a conditional loss of the Notch2 receptor, in vivo and in vitro chemical 
Notch signaling inhibition, and reporter gene studies we demonstrate Hsd11b1 is a 
novel Notch signaling target in the developing pituitary. To understand how loss of 
Hsd11b1 in Notch2 cKO mice may influence corticotrope differentiation, we 
characterized its expression during pituitary development and generated mice with a 
conditional loss of Hsd11b1 in Pomc expressing cells (Hsd11b1 cKO) to determine the 
function of this gene in the developing pituitary. We show that Hsd11b1 expression is 
dynamic but is most prominent during postnatal pituitary development, a time point in 
which Notch2 appears to be a crucial regulator of corticotrope differentiation. In addition, 
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conditional loss of Hsd11b1 results in increased expression of corticotrope-specific 
genes including Pomc and Crhr1 during postnatal development, similar to Notch2 cKO 
mice.  Interestingly, our studies also imply 11β-HSD1 is an important regulator of 
melanotrope gene expression. These data suggest Notch regulation of Hsd11b1 may 
be part of the mechanism influencing corticotrope lineage development.  
MATERIALS AND METHODS 
Mice 
Notch2 cKO mice were generated as previously described. Briefly, Notch2fl/fl mice 
(Jackson Laboratories) were bred to Foxg1+/cre mice (Jackson Laboratories).  Notch2+/fl; 
Foxg1+/cre, and Notch2+/fl; Foxg1+/+ littermates were bred to generate cKO animas. For 
genotyping, tail biopsies were collected and DNA extraction using HotSHOT protocol 
was performed (Truett et al., 2000). Genotype was determined by PCR for Cre and 
Notch2 alleles using previously published primers (Hébert and McConnell, 2000; 
McCright, Lozier and Gridley, 2006). Wild-type mice of mixed genetic background were 
used for Hsd11b1 and Nr3c1 mRNA expression analysis at different ages and 11β-
HSD1 protein localization experiments.  
To generate Hsd11b1 cKO mice, Hsd11b1fl/fl mice, provided by Dr. Gareth Lavery 
(University of Birmingham, Birmingham, UK), were bred to Pomc+/cre mice purchased 
from Jackson Laboratories (Balthasar et al., 2004). Hsd11b1fl/fl; Pomc+/cre and 
Hsd11b1fl/fl were bred together to generate cKO animals. Tails biopsies were collected, 
and DNA was extracted as previously described. Genotyping for Pomc+/cre and Hsd11b1 
alleles was determined by PCR using previously published primers (Goldberg, Aujla and 
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Raetzman, 2011; Lavery et al., 2012).  For all experiments using genetic mouse 
models, both male and female pituitaries were used.   
Male and female CD-1 mice (Charles River) from a breeding colony maintained in our 
laboratory were used for all of the following experiments: in vivo, N-[N-(3,5-
Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester (DAPT) treatment, primary 
pituitary cell cultures, pituitary explant treatment with (DAPT), dexamethasone (Dex), 
11-dehydrocorticosterone (11-DHC), and BVT. 2733. For in vitro experiments male and 
female pituitaries were pooled.  
All procedures with mice were done with the approval of the University of Illinois 
Institutional Animal Care and Use Committee. 
Quantitative RT-PCR (qRT-PCR) 
RNA was processed as previously described (Nantie et al., 2014). Briefly, RNA was 
isolated from individual pituitaries using RNAqueous micro kit. For e16.5, pnd1, pnd5, 
pnd6 and pnd10 pituitaries, total amount of RNA was used to synthesize cDNA from 
each pituitary using a ProtoScript M-Mulv First Strand cDNA Synthesis Kit (New 
England Biolabs). For pnd15, pnd21 and pnd60 animals, 0.5 μg of RNA was converted 
to cDNA. A no reverse transcriptase sample was prepared and used a negative control. 
For data analysis the standard comparative Δ cycle threshold value method was used 
as previously described (Goldberg, Aujla and Raetzman, 2011). Statistical significance 
was determined by Student's t-test. 
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DAPT injections  
In vivo, DAPT (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester, 
Gamma Secretase Inhibitor IX, Millipore) injection studies were performed as previously 
described (Nantie et al., 2014; Edwards et. al. 2016). Briefly, pnd2 mice were injected 
with 100 mg/kg/day DAPT diluted in dimethyl sulfoxide (DMSO, Sigma-Aldrich) or 
DMSO alone for 3 days and pituitaries were collected 24 hours after the last injection for 
qRT-PCR analysis.  
In situ hybridization (ISH) 
An antisense probe for Hsd11b1 was prepared from an I.M.A.G.E. clone vector 
containing full length Hsd11b1 cDNA (Clone ID: 40130641) (Source Bioscience). 
Hsd11b1 cDNA was amplified using T7 and T3 primers. The PCR product was then 
enzymatically digested with HindIII and the RNA probe was synthesized with T3 
polymerase (Promega) in the presence of digoxigenin-labeled nucleotides (Roche). 
Whole heads of pnd1 animals were fixed overnight in a zinc fixative (BD Pharmigen) 
and embedded in paraffin for sectioning. Slides were deparaffinized, rehydrated and 
incubated in a solution of 0.3% TX-100 (Sigma-Aldrich) for 15 minutes and 
subsequently permeabilized using Proteinase K (Life Technologies) for 15 minutes at 
37°C. Slides were fixed with 3.7% paraformaldehyde (Sigma-Aldrich) and acetylated in 
0.25% acetic anhydride diluted in triethanolamine (Sigma-Aldrich) buffer. Finally, slides 
were incubated with hybridization buffer and then incubated with denatured Hsd11b1 
probe overnight at 55°C. A subset of slides were incubated with hybridization buffer in 
 
 
94 
 
the absence of probe to serve as a negative control. Probe detection was performed as 
previously described (Nantie et al., 2014).  
Plasmids and vectors 
For the Hsd11b1 distal and proximal RBPJ site constructs, approximately 1000bp of the 
gene containing the identified sites were cloned into the pGL2 luciferase reporter vector 
upstream of an SV40 promoter (pGL2-Luc). PCR products from a bacterial artificial 
chromosome plasmid (RP23-451H2) (Source Bioscience) were obtained. The following 
primers were used for the distal and proximal constructs, respectively: forward primer, 
5’- GAGCTCGCTGCTGTGGTCATC-3’ and reverse primer, 5’-
CTCGAGCCCTTTCAACAAGTCTTCAG-3’, and forward primer, 5’- 
GAGCTCTGTCCTGACTGTGAACGG-3’ and reverse primer, 5’- 
CTCGAGGCTTTAATGGGACCAAAGTG-3’. The primers were designed to create a 
SacI restriction enzyme site on the 5’ end of the insert and XhoI site on the 3’ end. The 
resulting PCR products were cloned into a pGEM-T easy vector following the 
manufactures instruction (Promega) and subsequently subcloned into the pGL2-luc. For 
the distal RBPJ mutant construct, the conserved RBPJ binding motif approximately 71 
upstream of the distal promoter transcription start site was mutated using a site directed 
mutagenesis kit (Promega) with the following mutagenic primers; forward primer, 5’- 
TTGTATCAGGTGGCAGA-3’ and reverse primer, 5’- CAGACCTGTTAGCCCTA-3’. The 
pHes1-Luc vector was a gift from Dr. Ryoichiro Kageyama (Kyoto University). The 
NOTCH2 expression plasmid (3XFlagNICD2) was a gift from Raphael Kopan (Addgene 
plasmid # 20184) (Ong et al., 2006).  
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 Pituitary progenitor cell culture and transfection  
The following protocol was adapted from Chen et al., 2005. Pituitary cells were cultured 
in media containing growth factors that enrich for the expansion of the progenitor cell 
population. Briefly, pnd3 CD-1 pituitaries were dissected, and the posterior lobe was 
discarded. Pituitaries were pooled and enzymatically digested in 0.25% Trypsin (Sigma 
Aldrich) for 30-45 minutes at 37°C. The enzyme-digested pituitary cell suspension was 
then treated with 2000 U/ml DNAse I (Worthington Biochemical) for 10 minutes at 37°C 
and the enzyme was inactivated by adding equal volumes of 10% horse serum (Life 
Technologies) in Hank’s Balances salt solution (HBSS) (Corning). Suspensions are then 
triturated and spun down at 800 x g for 5 minutes. Supernatant was removed, and cells 
are resuspended in media containing DMEM/F12 (Life Technologies), 1% 
Penicillin/Streptomycin (Fisher Scientific), 1X B27 (Life Technologies), 20 ng/ml rhFGF 
(R&D Systems) and 20ng/ml rmEGF (R&D Systems). Cells were passed through a 40-
micron filter to ensure a single cell suspension and subsequently plated at 50,000 cell/ 
ml into 6 well ultra-low attachment plates (Corning). A media change was performed on 
day three in culture. On day four in culture, plasmid transfections using Lipofectamine 
2000 (Life Technologies) were performed. Cells were transfected at a DNA to 
Lipofectamine ratio of 1:5. Lipofectamine transfection was performed according to 
manufacturer’s protocol. Briefly, Lipofectamine reagent was diluted in Opti-MEM media 
(Life Technologies) and incubated for 15 minutes. Reporter constructs were then 
combined with Opti-Mem media. For each reporter 1.5 μg of plasmid was used in 
combination with 1 μg of 3XFlagNICD2 expression plasmid or an empty 3xFlag vector. 
In addition, all cells were transfected with 0.5 µg of a pCMV-Renilla luciferase reporter 
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construct for normalization. The diluted Lipofectamine was then added to the DNA and 
incubated for 20 minutes. Finally, the DNA/Lipofectamine mix is added to primary 
pituitary cells. Cells are harvested 24 hours after transfection and luciferase signal is 
detected using the Dual-Luciferase Reporter Assay System (Promega). For each 
reporter condition 3 wells were transfected individually and then pooled prior to 
Luciferase Assay. Reporter gene activity for luciferase constructs co-transfected with 
NICD2 was calculated as fold change compared to constructs co-transfected with an 
empty expression vector. Statistical significance was determined by Student’s t-test.  
Pituitary explant culture treatment with DAPT, dexamethasone, 11-DHC and BVT. 2733  
For the 48-hour DAPT treatment studies, pituitaries were treated as previously 
described (Nantie et al., 2014). Briefly, pnd3 pituitaries were dissected and cultured in 
96 well plate. Pituitaries were culture in media containing DMEM/F-12 media (Cellgro) 
supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin streptomycin 
(Fisher). At the start of the culture, 10uM DAPT diluted in DMSO or DMSO alone were 
added to cell culture media. After 24 hours, media was spiked with DAPT or DMSO and 
pituitaries were cultured for an additional 24 hours after which time pituitaries were 
harvested for RNA analysis. For pituitary explants treated with dexamethasone (Dex) 
(Tocaris bioscience), 11-dehydrocorticosterone (11-DHC) (US Biological), and BVT. 
2733 hydrochloride (BVT 2733) (Axon Medchem), pnd3 pituitaries were dissected and 
cultured on Millicell CM 24-well plate culture inserts (Millipore) in culture media 
containing DMEM/F12 medium (Life Technologies), 10% charcoal stripped Fetal Bovine 
Serum (FBS) (Sigma), and 1% Penicillin/Streptomycin (Fisher Scientific). Pituitaries 
were treated with the following compounds for 6 hours; DMSO alone, 100 nM Dex 
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diluted in DMSO or, 10nM 11-DHC diluted in DMSO, alone or in the presence of 100 μM 
BVT. 2733 diluted in DMSO. To determine long term effects of 11β-HSD1 inhibition 
pituitaries were also treated with DMSO or 10 μM BVT 2733 for 48 hours.  
Immunohistochemistry (IHC) 
For analysis of Hsd11b1 cKO mice and controls, whole heads of pnd6 mice were fixed 
in 3.7% paraformaldehyde diluted in phosphate buffered saline (PBS) and embedded in 
paraffin for sectioning. Slides were then deparaffinized, rehydrated and washed in PBS. 
For immunohistological detection of PAX7, samples were subjected to a 10mM citrate 
boil for 10 minutes as a means of antigen retrieval. All samples were incubated in a 
blocking solution containing 5% normal donkey serum (Jackson Immunoresearch), 3% 
bovine serum albumin (Jackson Immunoresearch) and 0.5% TritonX-100 (Sigma 
Aldrich) diluted in PBS for 1 hour at room temperature.  Primary antibodies used were 
raised against the following peptides: POMC (1:1000, DAKO), PAX7 (1:500, 
Developmental Studies Hybridoma Bank), and GH, TSHβ and LHβ (1:1000, Dr. A. F. 
Parlow from the National Hormone and Peptide Program). Slides were incubated with 
primary antibody overnight at 4C. Following the primary antibody, slides were incubated 
with a biotin-conjugated mouse (PAX7) or rabbit (POMC, GH, TSHβ, LHβ) secondary 
antibody (1:250, Jackson ImmunoResearch) followed by streptavidin-conjugated cy3 
(1:250, Jackson ImmunoResearch) fluorophore. For 11β-HSD1 and POMC 
colocalization studies, pnd1 pituitaries were zinc fixed and embedded in paraffin for 
sectioning. Samples were subjected to a 1 minute boil and 5 minute hot bath in 10mM 
citrate and incubated in blocking solution as mentioned previously. Slides were first 
incubated with 11β-HSD1 (1:100, Abcam) primary antibody overnight at 4°C, then 
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incubated with rabbit cy3 conjugated secondary antibody. Samples were then incubated 
with a blocking solution (3% bovine serum albumin [Jackson ImmunoResearch] and 
0.5% Triton X-100 [Sigma Aldrich] diluted in PBS), 1% Peroxidase-conjugated 
streptavidin (Jackson ImmunoResearch) and 1% Donkey anti-rabbit IgG (Jackson 
ImmunoResearch). After blocking, slides were incubated with POMC (1:1000) primary 
antibody followed by biotin conjugated rabbit secondary antibody (1:250, Jackson 
ImmunoResearch) and streptavidin-conjugated cy2 (1:250, Jackson ImmunoResearch) 
fluorophore.  All slides were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 
1:1000, Life Technologies) and visualized at 100x, 200x or 400x magnification using 
Leica DM2560 microscope.  
Corticotrope cell number quantification 
Corticotrope quantification was determined by calculating the percent of POMC positive 
cells in the anterior lobe (AL) as previously described (Nantie et al., 2014). Five to six 
equally spaced slides were immunohistochemically stained using a POMC primary 
antibody and counterstained with DAPI. For each pituitary, a ratio of cells per area was 
determined by counting the number of DAPI positive cells within a given area. This ratio 
was used to determine the total number of DAPI cells in the AL of each pituitary section. 
For each pituitary section the number of POMC positive cells in the AL lobe was 
counted and divided by the total number of AL cells to calculate the percent of 
immunopositive cells.  Statistical significance was determined by Student's t-test. 
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Adrenal and hormonal analysis  
Restraint stress was performed on pnd60, as previously described (Goldberg et al., 
2011). Briefly, male and female, Hsd11b1 cKO and control mice were subjected to 10 
minutes of restraint stress in a ventilated polypropylene 50 ml conical tube between 
0800h and 1000h. Mice were sacrificed immediately after restraint stress using CO2 
inhalation. Blood was collected via cardiac puncture and stored into EDTA-coated tubes 
(BD Microtainer) and spun down at 2300 x g for 10 minutes at 4°C. Plasma was 
collected and stored at -80C until needed. Plasma corticosterone levels were measured 
using a Corticosterone Enzyme Immunoassay kit (ENZO Life Sciences) per 
manufacturers protocol. Samples were tested in duplicate and statistical significance 
was determined using Student’s t-test. The right adrenal gland of each animal was 
collected and weighed.  All females were in diestrus at the time of testing.  
RESULTS 
The Notch signaling pathway is a novel regulator of Hsd11b1 in the postnatal pituitary. 
To demonstrate Notch regulation of Hsd11b1, we conducted in situ hybridization (ISH) 
and quantitative RT-PCR (qRT-PCR) analysis comparing Hsd11b1 expression in 
Notch2fl/flFoxg1/cre (Notch2 cKO) and control pituitaries at postnatal day 1 (pnd1). In 
control animals, Hsd11b1 is highly expressed in both the intermediate lobe (IL), and in 
distinct populations of cells within the anterior lobe (AL) parenchyma. In addition, 
Hsd11b1 mRNA expression is present in the marginal cells lining the lumen in the IL 
and AL (Fig. 4.1A, 4.1C).  In contrast, Hsd11b1 expression is markedly reduced in 
Notch2 cKO mice. The most dramatic loss of expression appears in the IL, as very little 
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Hsd11b1 mRNA is detectable in the marginal or parenchymal cells (Fig. 4.1B). Hsd11b1 
expression does appear reduced in the AL, albeit to a lesser extent compare to the IL 
(Fig. 4.1D). In agreement with this observation, qRT-PCR analysis shows an almost 
80% reduction in Hsd11b1 mRNA levels in Notch2 cKO pituitaries compared to wildtype 
littermates (Fig. 4.1E).  Notch2 cKO mice have decreased Notch2 from as early as 
embryonic day 8.5 (e8.5), although the phenotype is primarily observed postnatally 
(Nantie et al., 2014). We therefore treated mice specifically during postnatal 
development with the gamma secretase inhibitor N- [N-(3,5- difluorophenacetyl-L-
alanyl)]-S-phenylglycine t-butyl ester (DAPT) to determine if acute Notch signaling 
inhibition is sufficient to decrease Hsd11b1 mRNA levels. A significant reduction in 
Hsd11b1 expression is observed in DAPT treated animals compared to vehicle treated 
controls (Fig. 4.1F). Next, pituitary explants were treated in culture with DAPT for 48 
hours to determine if the regulation of Hsd11b1 by Notch signaling can occur directly at 
the level of the pituitary. A significant decrease in Hsd11b1 mRNA was observed in 
pituitary explants treated in culture with DAPT compared to vehicle treated controls (Fig 
4.1G). To assess the potential for direct regulation by the Notch signaling pathway the 
regulatory regions of the Hsd11b1 gene were scanned for putative RBPJ binding motifs. 
The Hsd11b1 gene contains two distinct promoters, a distal P1 promoter approximately 
20K base pairs away from the first exon and a proximal P2 promoter located directly 
adjacent to the first exon (Moisan et al., 1992; Staab et al., 2011). We identified multiple 
putative RBPJ biding motifs adjacent to or within the proximal and distal promoter 
regions. In addition, the site identified 71 base pairs upstream of the distal promoter is 
conserved between mice and humans (Fig. 4.1H). To determine functionality of the 
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identified RBPJ sites, primary pituitary cell-based reporter assays were conducted. 
Approximately 1000bp of the Hsd11b1 gene containing either the proximal (Proximal 
RBPJ) or distal sites (Distal RBPJ) were cloned into a luciferase vector and transfected 
into primary pituitary progenitor cultures in the presence of the Notch2 intracellular 
domain expression plasmid (NICD2) or an empty expression plasmid. As an 
experimental control we demonstrated that co-transfection of NICD2 results in 
increased Hes1 promoter activity. For the Hsd11b1 constructs, NICD2 expression 
induced reporter gene activity for the Distal RBPJ construct but not the Proximal RBPJ 
construct. Mutation of the conserved RBPJ site resulted in attenuated regulation of the 
reporter gene activity in the presences of NICD2 (Fig. 4.1I). Taken together, our results 
demonstrate that Hsd11b1 is highly expressed in the postnatal pituitary and its 
expression is Notch signaling dependent. Furthermore, our reporter gene assay studies 
suggest the Notch signaling pathway may directly regulate expression of Hsd11b1 in 
the developing pituitary.  
Hsd11b1 and Nr3c1 are dynamically expressed in the developing pituitary.  
The temporal and spatial expression patterns of Hsd11b1 have been relatively 
unexplored in the pituitary. We therefore examined Hsd11b1 expression at several 
timepoints during pituitary development to help elucidate specific developmental 
windows in which the pituitary may be sensitive to 11β-HSD1 activity and to identify a 
time during which Notch regulation of this gene may be particularly important. In 
addition, we also characterized gene expression of glucocorticoid receptor alpha 
(Nr3c1), as many effects of 11β-HSD1 will presumably act through a glucocorticoid 
receptor dependent pathway. Hsd11b1 mRNA expression appears relatively low during 
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embryonic development compared to adult animals. Interestingly, Hsd11b1 levels peak 
during the first week of postnatal life specifically at pnd5. By pnd9, levels are similar to 
those seen in the adult and a significant increase in expression is detected at pnd21 
(Fig. 4.2A). Nr3c1 mRNA levels are higher during embryonic development, compared to 
adult animals.  However, a similar pattern of expression is observed at pnd5, in which a 
peak in Nr3c1 expression is observed (Fig. 4.2B). Next, we used immunohistochemistry 
to determine protein localization of 11β-HSD1 in the postnatal pituitary. 11β-HSD1 is 
highly expressed in the both the AL and IL of the postnatal pituitary (Fig. 4.2C). The 
pattern of protein and gene expression suggest that 11β-HSD1 is highly expressed in 
corticotropes and melanotropes. Expression of 11β-HSD1 in corticotropes and 
melanotropes was determined by colocalization of with POMC in the AL and IL, 
respectively. In the AL, the majority of corticotropes appear to be positive for 11β-HSD1 
however not all 11β-HSD1 positive cells co-express POMC (Fig. 4.2D). In the IL, nearly 
all melanotropes appear to express 11β-HSD1 (Fig. 4.2E). These data indicate that 
11β-HSD1 is highly expressed in POMC expressing cells but also appears to be 
expressed in other pituitary cell lineages.  Taken together, these data suggest that both 
Hsd11b1 and Nr3c1 are dynamically expressed throughout pituitary development in 
multiple pituitary cell types and the first week of postnatal pituitary development may be 
particularly sensitive to 11β-HSD1 activity and glucocorticoid signaling.  
11β-HSD1 is active in the postnatal pituitary 
To assess if 11β-HSD1 could potentially act as a mediator of Notch signaling that 
influences corticotrope specification we first wanted to determine if 11β-HSD1 activity 
regulates corticotrope gene expression in vitro. Previous studies in mice with a global 
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loss of Hsd11b1 demonstrate that it is the only enzyme capable metabolizing the 
inactive glucocorticoid (GC), 11-dehyrocorticosterone (11-DHC) into its active form 
corticosterone (Kotelevtsev et al., 1997). Therefore, to demonstrate 11β-HSD1 is active 
during postnatal pituitary development, we treated pituitary explants acutely with 11-
DHC and examined the expression of proopiomelanocortin (Pomc) and dexamethasone 
induced Ras related protein 1 (Rasd1), a gene that is potently induced by the active 
GCs. As a positive control, pituitaries explants were also treated acutely with the 
synthetic glucocorticoid receptor agonist dexamethasone (Dex). Treatment with Dex 
results in a significant decrease in Pomc mRNA levels and an increase in Rasd1 mRNA 
levels (Fig. 4.3A). Similarly, Pomc expression was decreased and Rasd1 expression 
was increased with 11-DHC treatment (Fig. 4.3B). In addition, the apparent decrease in 
Pomc mRNA in response to 11-DHC treatment is attenuated when pituitaries are co-
treated with 11-DHC and the 11β-HSD1 specific inhibitor, BVT. 2733 (Fig. 4.3C). To 
determine the effects of prolonged inhibition of 11β-HSD1 on POMC lineage gene 
expression, pituitaries were treated with BVT. 2733 for 48 hours.  BVT. 2733 treatment 
results in increased Pomc and Tpit mRNA levels, a gene necessary for melanotrope 
and corticotrope differentiation (Fig. 4.3D). Our data demonstrate that 11β-HSD1 is 
active in the postnatal pituitary and regulates expression of glucocorticoid responsive 
genes including genes related to corticotrope differentiation and function. In addition, 
alterations in Tpit expression suggests 11β-HSD1 activity may influence changes in 
POMC lineage differentiation. Finally, these data demonstrate that postnatal 
development is a time in which the pituitary would be sensitive to alterations in 
glucocorticoid signaling.  
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Generation of Hsd11b1 conditional knockout mouse  
Mice with a conditional loss of Hsd11b1 in Pomc expressing cells, Hsd11b1fl/flPomc+/cre 
(Hsd11b1 cKO), were generated to help elucidate the function of 11β-HSD1 in the 
pituitary and to examine the potential contribution of loss Hsd11b1 to the corticotrope 
phenotype observed in Notch2 cKO pituitaries. Hsd11b1 is highly expressed in POMC 
expressing cells but is also present in other endocrine cell types. Quantitative PCR 
could not be used to demonstrate a reduction in Hsd11b1 expression in our conditional 
knockout mice because of a possible compensatory increase in Hsd11b1 in other 
endocrine cell lineages. We used a genomic DNA PCR analysis to demonstrate that 
expression of Cre recombinase under the direction of the Pomc promoter results in 
excision of catalytic domain (exon5) of the Hsd11b1 gene specifically in the pituitary 
(Fig. 4.4A). To assess 11β-HSD1 activity we analyzed Pomc mRNA expression in WT 
and Hsd11b1 cKO pituitaries treated in culture with 11-DHC or vehicle control. As 
previously shown, WT pituitaries treated with 11-DHC show a significant reduction in 
Pomc mRNA levels. In contrast, Hsd11b1 cKO pituitaries show no change in Pomc 
gene expression after 11-DHC treatment, demonstrating loss of 11β-HSD1 enzymatic 
activity in the cKO (Fig.4.4B).  
Conditional loss of Hsd11b1 alters corticotrope and melanotrope gene expression 
Lineage specific markers for both melanotropes and corticotropes were examined in 
Hsd11b1 cKO mice at pnd6, a timepoint in which an increase in corticotrope cell 
number was observed in Notch2 cKO pituitaries (Nantie et al., 2014). Hsd11b1 cKO 
mice have significantly increased Pomc mRNA levels compared to control animals, 
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whereas no significant difference in Tpit gene expression is observed (Fig. 4.5A). In 
addition, corticotrope specific gene expression is also affected in Hsd11b1 cKO mice. 
Similar to Notch2 cKO mice, we observe an increase in Crhr1 mRNA levels in Hsd11b1 
cKO pituitaries. In contrast, expression of Neurod1, a gene known to regulate Pomc 
expression in corticotropes remains unchanged in Hsd11b1 cKO mice compared to 
control animals (Fig. 4.5B) (Lamolet et al., 2004; Poulin et al., 1997). To determine if the 
changes observed in corticotrope specific gene expression are due to a difference in 
cell number, POMC expressing cells in the anterior lobe of were quantified in control 
and Hsd11b1 cKO pituitaries. No differences in anterior lobe morphology or corticotrope 
cell number are detected in Hsd11b1 cKO pituitaries (Fig. 4.5D, 4.5E and 4.5J). 
Surprisingly, in contrast to the observed increase in corticotrope gene expression, 
melanotrope specific genes are decreased in Hsd11b1 cKO pituitaries. Expression of 
Pax7, a pioneering factor necessary for the specification of melanotropes, and Dll3, a 
maker of the melanotrope population is significantly reduced in Hsd11b1 cKO mice 
compared to control littermates (Fig. 4.5C). There did not appear to be an obvious 
change in POMC expression or morphology in IL of Hsd11b1 cKO animals (Fig. 4.5F 
and 4.5G). However, in agreement with decreased gene expression, PAX7 protein 
expression is decreased in melanotropes of Hsd11b1 cKO pituitaries (Fig. 4.5H and 
4.5I). These data suggest the increase in corticotrope cell number observed in Notch2 
cKO pituitaries is not solely a consequence of reduced Hsd11b1 expression in 
corticotropes but may contribute to changes in corticotrope gene expression observed 
in Notch2 cKO mice. Most surprisingly our data suggests that 11β-HSD1 may be an 
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upstream regulator of the pioneer factor PAX7, indicating a role for 11β-HSD1 in 
melanotrope specification.  
Hormones and lineage specific genes are unaffected in non-POMC expressing cells in 
Hsd11b1 cKO mice at pnd6.  
11β-HSD1 is known to regulate tissue specific levels of active glucocorticoids. This 
could indicate that even though our mouse model has decreased expression of 
Hsd11b1 in Pomc expressing cells only, other cells have the potential to be affected due 
to paracrine signaling between the different pituitary cell types. Therefore, we examined 
expression of lineage specific transcription factors and hormones in non-POMC 
expressing cells in Hsd11b1 cKO mice. No difference in mRNA expression of the 
pituitary progenitor/stem cell transcription factor Sox2, is observed between control and 
Hsd11b1 cKO mice (Fig. 4.6A). Control and Hsd11b1 cKO pituitaries have no significant 
difference in Pou1f1 (Pit1) mRNA levels, a transcription factor that is necessary for the 
differentiation and hormone expression in somatotropes, lactotropes and thyrotropes. In 
addition, Gh mRNA levels are not changed in Hsd11b1 cKO pituitaries compared to 
controls (Fig. 4.6B). Somatotropes are present throughout the AL parenchyma of control 
pituitaries and appear unchanged in Hsd11b1 cKO pituitaries (Fig. 4.6D and 4.6E). 
Similarly, thyrotropes are detected in the AL parenchyma and appear to be unaffected 
in Hsd11b1 cKO pituitaries compared to controls (Fig. 4.6F and 4.6G). Lhb mRNA 
expression is not significantly different between control and Hsd11b1 cKO pituitaries in 
males or females (Fig. 4.6C). In addition, we did not observe any changes in the 
gonadotrope cell localization or expression of LHβ in Hsd11b1 cKO compared to 
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controls (Fig.4.6H and 4.6I). This data suggests that development and function of the 
other pituitary lineages is not affected in Hsd11b1 cKO mice.  
Hypothalamic-Pituitary-Adrenal Axis function appears to be normal in Hsd11b1 cKO  
To further elucidate the function of 11β-HSD1 in the pituitary and to understand how the 
loss of Hsd11b1 could potentially affect the HPA axis in the adult animal, we analyzed 
the functionality of the HPA axis in Hsd11b1 cKO mice. Previous studies in mice with a 
global loss of Hsd11b1 show elevated corticosterone levels after restraint stress 
implying an impaired negative feedback response (Harris et al., 2001). To determine if 
loss of Hsd11b1 in the pituitary alone is sufficient to cause impaired negative feedback, 
control and Hsd11b1 cKO mice at pnd60 were subjected to restraint stress and 
corticosterone levels were measured. There were no observed differences in stress-
induced corticosterone levels between Hsd11b1 cKO and their wildtype counterparts 
(Fig. 4.7A). In addition, Pomc mRNA levels are similar between Hsd11b1 cKO and 
control animals after restraint stress (Fig. 4.7B). Lastly, we measured adrenal gland 
weights in control and Hsd11b1 cKO mice as changes in adrenal gland weight are often 
indicative of HPA axis dysfunction. Relative adrenal gland weights are not significantly 
different between control and Hsd11b1 cKO mice. Our assessment of HPA axis 
functionality in Hsd11b1 cKO mice suggests that loss of Hsd11b1 in Pomc expressing 
cells does not affect overall function of the HPA axis.  
DISCUSSION 
The Notch signaling pathway coordinates two key developmental processes in the 
pituitary: the maintenance and self-renewal capacity of stem/ progenitor cells and cell-
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fate determination of the differentiated cell types. In particular, this pathway controls the 
balance of PIT1 and POMC lineages differentiation, though the mechanism by which 
Notch mediates these cell-fate decisions remains unclear. Notch signaling is thought to 
promote expansion of the PIT1 lineage through regulation of the pituitary specific 
transcription factor, Prop1 (Nantie et al., 2014; Zhu et al., 2006). Conversely, few 
studies have identified factors that contribute to Notch dependent suppression of 
corticotrope differentiation. Therefore, we sought to identify novel Notch signaling 
targets whose function may contribute to suppression of the corticotrope cell fate. Our 
study is the first identify Hsd11b1, a pre-receptor regulator of glucocorticoid (GC) 
signaling, as a Notch signaling target gene. These studies are the first to demonstrate 
11β-HSD1 functions to suppress expression of corticotrope specific genes during early 
postnatal pituitary gland development. Therefore, Notch signaling may regulate this 
gene as a potential mechanism to influence corticotrope specification. In addition, 11β-
HSD1 regulates melanotrope gene expression, suggesting glucocorticoids are important 
regulators of melanotrope specification. Taken together, our studies suggest that 
dynamic crosstalk between the Notch signaling and glucocorticoid signaling pathways 
play a key role in pituitary gland development.  
Notch signaling is a potent regulator of Hsd11b1 expression in the postnatal pituitary. 
This was demonstrated by a drastic reduction Hsd11b1 in Notch2 cKO mice at postnatal 
day 1 (pnd1).  Furthermore, in vivo and in vitro treatment of postnatal mice with DAPT, a 
gamma secretase inhibitor, resulted in a significant decrease in Hsd11b1 expression. 
These data suggest that the Notch signaling regulation of Hsd11b1 can occur 
specifically during the postnatal window at the level of the pituitary and the reduction in 
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Hsd11b1 in Notch2 cKO pituitary is not simply a confounded effect of long term loss of 
Notch signaling. In addition, our identification of putative RBPJ binding motifs and 
reporter gene assays suggest Hsd11b1 is a direct transcription target of the Notch 
signaling pathway. While our data suggests the potential for direct Notch regulation, 
future studies will need to be conducted to prove this definitively.  
To our knowledge no previous studies in the pituitary have established a connection 
between the Notch and glucocorticoid signaling pathways. However, crosstalk between 
these two pathways have been made in other tissues. For example, in the liver it has 
been shown that GCs and the canonical downstream Notch signaling target Hes1 have 
opposing functions. Hes1 gene expression is silenced in response to glucocorticoid 
signaling and Hes1 appears to repress GR dependent gene expression (Revollo et al., 
2013). In contrast, studies examining the effects of GCs on hippocampal neurogenesis 
suggest that low levels of GCs actually activate the Notch signaling pathway (Anacker 
et al., 2013). Taken together, these studies suggest that crosstalk between the Notch 
and GC signaling pathways occurs in multiple systems, however the dynamics of their 
interaction appear to be tissue specific.  Our studies indicate regulation of Hsd11b1 may 
be an important link between the Notch and glucocorticoid signaling pathways and 
suggests a novel mechanism of controlling pituitary gland development.   
11β-HSD1 is a pre-receptor regulator of glucocorticoid action in numerous tissues and 
our studies are the first to describe its actions in the postnatal pituitary. Previous studies 
in mouse and humans show that mRNA expression 11-beta hydroxysteroid type 1 and 2 
isozymes are mis-regulated in corticotrope adenomas (Korbonits et al., 2001; Nigawara 
et al., 2006).  A similar phenomenon has been observed in canine corticotrope 
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adenomas. Furthermore, treatment of canines with carbenoxolone (CBX), an inhibitor of 
both type 1 and type 2 11 beta- hydroxysteroid dehydrogenase isoforms results in 
altered gene expression of Hsd11b1 and Hsd11b2 and Pomc (Teshima et al., 2015). 
While these studies provide evidence that 11β-HSD1 is present in the pituitary and has 
the potential to regulate expression of Pomc mRNA in a tumor setting, they do not 
assess the specific functions of 11β-HSD1 in the pituitary. We show Hsd11b1 is present 
throughout pituitary development and is particularly important during postnatal pituitary 
development. In addition, our functional studies in vitro and with conditional knockout 
mice demonstrate 11β-HSD1 is a regulator of corticotrope and melanotrope gene 
expression.  
Glucocorticoids are known regulators of pituitary development and function, as mice 
with reduced systemic glucocorticoids or reduced glucocorticoid receptor levels in the 
pituitary have altered corticotrope gene expression and increased corticotrope cell 
number. Our studies expand upon this knowledge and show that 11β-HSD1, as a 
regulator of intra-cellular glucocorticoid availability, plays an important in the modulation 
of corticotrope gene expression. Similar alterations in corticotrope gene expression 
were observed between Hsd11b1 cKO and Notch2 cKO mice, however we did not 
observe any difference in corticotrope cell number in Hsd11b1 cKO. This suggests loss 
of Hsd11b1 in Pomc expressing cells alone is not sufficient to drive changes in 
corticotrope cell number. Based on our in situ hybridization and immunohistological 
studies, 11β-HSD1 appears to be widely expressed in the developing pituitary. In 
addition, we see a drastic reduction of Hsd11b1 in Notch2 cKO pituitaries suggesting 
that expression is lost in multiple cell lineages. This may suggest that 11β-HSD1 
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expression in additional cell types, for example in stem cells or transit amplifying cells, is 
required to help dictate the balance of corticotrope differentiation and therefore, our 
current conditional knockout will not capture this regulation. This idea is supported by 
our in vitro studies in which we treat the entire pituitary with an 11β-HSD1 specific 
inhibitor. In this model of 11β-HSD1 inhibition we observe an increase both Pomc and 
Tpit mRNA expression. Tpit is required for the terminal differentiation of the 
melanotropes and corticotropes and altered expression of this gene is associated with 
changes in POMC lineage cell number (Pulichino et al., 2003). Therefore, our in vitro 
studies may suggest a potential change in POMC lineage cell number when 11β-HSD1 
activity is inhibited in multiple pituitary cell types. Taken together, these data 
demonstrate that Hsd11b1 is a novel regulator of corticotrope gene expression. 
Additionally, our findings suggest the increase in POMC lineage and corticotrope gene 
expression observed in Notch2 cKO mice may be due in part to loss of Hsd11b1 in 
POMC expressing cells. Furthermore, the fact that corticotrope number is increased in 
Nr3c1POMCCre mice but not in our models suggests activity of the glucocorticoid signaling 
pathway is sufficient to maintain the right number of corticotropes in Hsd11b1 cKO 
mice, perhaps due to the contribution of systemic glucocorticoids (Schmidt et al., 2009).   
Surprisingly, we also observed changes in melanotrope specific genes, an observation 
that was not seen in Notch2 cKO pituitaries. Specifically, Hsd11b1 cKO pituitaries have 
decreased expression of Pax7 mRNA and protein as well as decreased Dll3 mRNA 
levels at pnd6. PAX7 is a pioneer factor that acts a positive regulator of melanotrope 
cell fate. Loss of Pax7 (Pax7-/-) in the pituitary results in loss of melanotrope identity and 
the mis-expression of corticotrope specific genes in the intermediate lobe. The reduced 
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expression of PAX7, therefore could indicate that melanotrope cell number is decreased 
in response to reduced Hsd11b1 expression. This is further supported by the decrease 
in another melanotrope specific marker Dll3 (Raetzman et al., 2004).  This could 
indicate melanotrope identity is altered in the Hsd11b1 cKO mice. However, a partial 
reduction in Pax7 expression may not be sufficient to result in changes in melanotrope 
specification or number as mice with heterozygous loss of Pax7 have no melanotrope 
phenotype (Budry et al., 2012). The robust expression of Hsd11b1 in melanotropes and 
the altered expression of melanotrope specific genes in Hsd11b1 cKO animals was 
particularly surprising because melanotropes have relatively low expression of 
glucocorticoid receptor (Budry et al., 2012). These observations indicate that 11β-HSD1 
functions to regulate activation of other receptors modulated by glucocorticoids such as 
the mineralocorticoid receptor in melanotropes. Taken together, these data demonstrate 
11β-HSD1 is a novel regulator of melanotrope gene expression. In addition, 11β-HSD1 
may play a role in melanotrope identity however further studies are necessary to prove 
melanotrope identity is affected in Hsd11b1 cKO mice.  
It is known that global loss of Hsd11b1 results in altered Hypothalamic-Pituitary- 
Adrenal (HPA) functionality in adult mice due to impaired negative feedback (Abrahams 
et al., 2012; Carter et al., 2009; Harris et al., 2001).  However, it is unknown how loss of 
Hsd11b1 at the level of the pituitary contributes to this phenotype. We now demonstrate 
alterations in 11β-HSD1 at the level of the pituitary does not substantially impact HPA 
axis functionality. However, compensatory mechanisms could be in place at other levels 
of the HPA axis such as the hypothalamus or adrenal gland to combat loss in the 
pituitary.  
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Our current study has identified Hsd11b1 as a novel Notch signaling target in the 
developing pituitary which plays an important role in POMC lineage gene expression 
during early postnatal pituitary development. Our studies establish 11β-HSD1 as a 
novel link between the Notch signaling and Glucocorticoid signaling pathway, 
highlighting a novel mechanism to influence pituitary gland development.  
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FIGURES 
Figure 4.1: Notch signaling regulates Hsd11b1 expression in the postnatal pituitary. In 
situ hybridization analysis reveals that Hsd11b1 expression is robust in the pituitary at 
postnatal day 1 (pnd1) in control mice (A and C). Expression appears to be highest in 
the cells surrounding the pituitary cleft with scattered expression throughout the anterior 
lobe (AL) and intermediate lobe (IL) parenchyma.  In Notch2 cKO mice, Hsd11b1 
expression is drastically reduced in IL cleft cells and in the IL parenchyma (B). Hsd11b1 
expression is reduced in AL marginal and parenchymal cells in Notch2 cKO mice 
compared to controls, albeit to a lesser extent than is observed in the IL (B and C). qRT-
PCR analysis shows a significant reduction in mRNA levels of Hsd11b1 in Notch2 cKO 
pituitaries compared to controls (E). Postnatal mice treated with DAPT have decreased 
pituitary Hsd11b1 mRNA levels compared to vehicle treated controls (F). Pituitary  
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Figure 4.1 (cont.)  
explants treated in culture with DAPT for 48 hours have decreased Hsd11b1 mRNA 
levels compared to vehicle treated controls (G).  Schematic representation of the 
Hsd11b1 gene including coding exons and proximal and distal promoter regions. 
Several RBPJ binding motifs were identified in or near regulatory regions of the 
Hsd11b1 gene. One RBPJ binding site is conserved between mouse and humans (*) 
(H). Primary pituitary progenitor cell cultures were transfected with the following 
luciferase reporter constructs; Hes1 promoter (Hes1 Prom.), Hsd11b1 distal RBPJ sites 
(Distal RBPJ), Hsd11b1 proximal RBPJ sites (Proximal RBPJ), and Hsd11b1 distal 
RBPJ mutant (Distal RBPJ Mut.), in the presence or absence of the Notch2 intracellular 
domain expression plasmid (NICD2). NICD2 expression induced reporter gene activity 
of the Hes1 promoter and Distal RBPJ constructs. No induction in reporter gene activity 
was observed in response to NICD2 for the Proximal RBPJ and Distal RBPJ mutant 
constructs (I). Firefly luciferase signals were normalized to pCMV-Renilla. Normalized 
vales are shown as relative fold change. Magnification, ×100 (A and B), and ×200 (C 
and D). Scale bars=50 μm. n=3-4 (ISH). n= 7 (qRT-PCR Notch2 cKO). n=8-10 (qRT-
PCR in vivo DAPT). n= 4-5 (qRT-PCR in vitro DAPT). n=3-4 independent replicates 
(Luciferase reporter assay). ***, p ≤ 0.001. *, p ≤ 0.05. 
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Figure 4.2: Hsd11b1 and Nr3c1 are dynamically expressed during pituitary 
development. Hsd11b1 mRNA levels are relatively low in the embryonic pituitary, rise 
after birth, and appear to peak during the first week of postnatal life and at pnd21 (A). 
Nr3c1 mRNA expression is higher during embryonic and postnatal development and at 
pnd21, compared to adult animal (B). All levels are compared to adult.11β-HSD1 is 
expressed throughout the IL and AL parenchyma (C). 11β-HSD1 (red) is present in the 
vast majority of POMC expressing cells (green) in the IL (D). The majority of POMC 
positive cells (green) co-express 11β-HSD1 (red) in the AL. Some 11β-HSD1 cells do 
not colocalize with POMC expression. Arrows indicate double labeled cells. 
Magnification, ×100 (C) ×400 (D and E). Scale bars=50 μm. n=3-4 (qRT-PCR). n=3 
(IHC) *, p ≤ 0.05.  
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Figure 4.3: 11β-HSD1 is active and regulates glucocorticoid responsive genes in the 
postnatal pituitary.  Treatment of pnd3 pituitary explant cultures with 100nM 
Dexamethasone (Dex) (A) or 10nM 11-dehydrocorticosterone (11-DHC) (B) for 6 hours 
resulted in decreased Pomc mRNA levels and increased mRNA levels of Rasd1, 
compared to vehicle treated controls. Co-treatment with 10nM 11-DHC and 100 μM 
BVT 2733, in culture for 6 hours resulted in attenuation of Pomc repression (C). Pituitary 
explant treatment with 10 μM BVT. 2733 for 48 hours resulted in increased Pomc and 
Tpit19 mRNA levels (D). n=10-15. ***, p ≤ 0.001. **, p ≤ 0.01 *, p ≤ 0.05.  
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Figure 4.4: Generation of Hsd11b1 cKO mice. PCR analysis of genomic DNA shows 
recombination of the Hsd11b1 gene occurs in the pituitary and not in the tail (A). Control 
and Hsd11b1 cKO pituitaries were treated in culture with 10nM 11-
dehydrocorticosterone (11-DHC) or vehicle for 6 hours. Pomc mRNA levels are 
decreased in control pituitaries treated with 11-DHC compared to vehicle treated 
controls. In contrast, no significant difference in Pomc mRNA is observed in Hsd11b1 
cKO pituitaries treated with 11-DHC treated compared to vehicle treated Hsd11b1 cKO 
pituitaries (B). n=5-10. *, p ≤ 0.05.  
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Figure 4.5: Corticotrope and melanotrope gene expression is altered in Hsd11b1 cKO 
mice at pnd6. At pnd6, Pomc mRNA levels are increased in Hsd11b1 cKO compared to 
controls, whereas Tpit mRNA expression is unchanged (A). mRNA levels of the 
corticotrope specific marker Crhr1 is increased in Hsd11b1 cKO and Neurod1 
expression is not changed (B). The melanotrope specific genes Pax7 and Dll3 are 
decreased in Hsd11b1 cKO pituitaries compared to controls (C). POMC expression, 
localization of corticotropes and morphology of the AL parenchyma appears similar in 
control (D) and Hsd11b1 cKO mice (E). The percentage of POMC positive cells in AL is 
not significantly different between Hsd11b1 cKO and control pituitaries (J).  POMC 
expression, localization of melanotropes and morphology of the IL appears to be similar 
between control (F) and Hsd11b1 cKO pituitaries (G). PAX7 is expressed exclusively in 
melanotropes in IL parenchyma (H). PAX7 expression is decreased in Hsd11b1 cKO 
mice compared to controls (I). Magnification, ×200 (D-I). Scale bars=50 μm. n=7-9 
(qRT-PCR). n=4-5 (POMC IHC and counts). n=3 (Pax7 IHC). ***, p ≤ 0.001. **, p ≤ 0.01 
*, p ≤ 0.05 
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Figure 4.6: Lineage specific genes and hormones are unaffected in non-POMC 
expressing cell types of Hsd11b1 cKO pituitaries.  There is no significant difference in 
mRNA levels of Sox2, Pou1f1 (Pit1), Gh, or Lhb between control and Hsd11b1 cKO 
mice at pnd6 (A, B and C). GH-positive somatotropes (D and E), TSHβ-positive 
thyrotropes (F and G) and LHβ-positive gonadotropes (H and I) are scattered 
throughout the AL parenchyma and appear to be similar in control and Hsd11b1 cKO 
pituitaries at pnd6. Magnification, ×200 (D-I). Scale bars=50 μm. n=3-9 (qRT-PCR). 
n=3-4 (IHC).  
 
 
 
 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: HPA activity appears normal in Hsd11b1 cKO mice. Control and Hsd11b1 
cKO mice were subjected to 10 minutes of restraint stress on postnatal day 60. Stress-
induced plasma corticosterone levels are similar between Hsd11b1 cKO and control 
mice (A). Pomc mRNA expression is not significantly different between Hsd11b1 cKO 
compared to control pituitaries (B). Adrenal gland weights are not significantly different 
between Hsd11b1 cKO and control animals. Control and Hsd11b1 cKO relative adrenal 
glands weights are significantly larger in female mice compared to male control and 
Hsd11b1 cKO mice (C). n=5-8 (all experiments). #, p ≤ 0.001. 
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CHAPTER 5: Conclusions and Discussion 
The pituitary functions as the central mediator of the endocrine system, interpreting 
peripheral signals and releasing hormones to regulate physiological functions such as 
growth, reproduction, metabolism, lactation and the response to stress. The pituitary 
exerts its control through the release of hormones from distinct populations of endocrine 
cell types within the gland including, somatotropes, gonadotropes, thyrotropes, 
lactotropes and corticotropes. The development and maintenance of the gland are 
dependent on the balance of pituitary progenitor maintenance and proliferation, and the 
coordinated differentiation of the endocrine cell types. Disruption in this balance can 
result in pituitary disorders such as hypopituitarism or the formation of pituitary tumors. 
In order to identify mechanisms of pituitary disease and to develop novel therapeutics 
for such diseases, it is important to determine the molecular signaling pathways that 
govern cell fate determination in the pituitary. Previous studies have demonstrated the 
importance of the Notch signaling pathway in pituitary gland development. The studies 
described in Chapter 3 and Chapter 4 elucidate novel mechanisms by which the Notch 
signaling pathway regulates progenitor cell maintenance and endocrine cell fate choice 
in the developing pituitary.  
Notch signaling regulates expression of GRHL2, a novel progenitor cell marker, in the 
postnatal pituitary  
The pituitary stem/progenitor cell population is identified based on expression of 
hallmark stem cell factors, such as SOX2, in distinct cell populations throughout pituitary 
gland development (Garcia-Lavandeira et al., 2009; Nantie et al., 2014). Current 
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research suggests the pituitary progenitor cells are necessary for pituitary expansion, 
maintenance, and response to physiological challenge. Previous studies from our 
laboratory demonstrated the importance of the Notch2 receptor in pituitary progenitor 
cell maintenance and proliferation during postnatal pituitary gland development. In 
Chapter 3, to help elucidate the mechanism by which Notch signaling influences the 
pituitary progenitor compartment, we sought to identify novel Notch target genes that 
are associated with stem cell function.  In this study, we identified grainyhead-like 2 
(Grhl2), a gene known to regulate progenitor cell plasticity, as a novel Notch regulated 
gene in the postnatal pituitary.  
Our study is the first to identify GRHL2 as pituitary progenitor cell marker. GRHL2 
follows a similar expression pattern to other pituitary progenitor factors such as SOX2, 
SOX9, and Notch signaling components (Nantie et al., 2014; Raetzman et al., 2004; 
Raetzman et al., 2007; Ward et al., 2005; Zhu et al., 2006). GRHL2 is detected 
throughout Rathke’s Pouch during embryonic development and becomes spatially 
restricted to marginal zone cells during postnatal development. In addition, co-
localization studies demonstrate GRHL2 is co-expressed in SOX2 expressing cells and 
rarely is detected in the endocrine cell types. These findings support the hypothesis that 
GRHL2 is a potential mediator of the Notch signaling pathway that influences the 
pituitary progenitor population.  
In addition, we utilized both chemical and genetic inhibition of Notch signaling to show 
GRHL2 is a novel Notch signaling target gene. Notch2 cKO mice have markedly 
reduced expression of the GRHL2 at postnatal day (pnd1). Interestingly, the loss of 
GRHL2 is not uniform in all pituitary progenitor cells, indicating that Notch regulation of 
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GRHL2 may be restricted to distinct progenitor cell compartments. This may suggest 
that there are multiple pituitary progenitor cell populations that function in different 
capacities to support pituitary expansion and maintenance throughout development. 
Therefore, Notch signaling, and its downstream targets may be important for regulating 
a specific subset of pituitary progenitors. In support of this idea, we observe Notch2 
cKO mice only display a progenitor phenotype during postnatal development, despite 
the fact Notch2 is present during embryonic development. Therefore, Notch2 activity 
may primarily function to maintain a population of pituitary progenitors that is specifically 
required for postnatal expansion of the gland.    
In addition, our studies using a chemical Notch inhibitor demonstrate Notch signaling is 
able to dynamically regulate the expression of Grhl2 similar to the canonical Notch 
signaling targets Hes1 and Hey1 (Nantie et al., 2014). This suggests that Grhl2 may be 
a direct transcriptional target of the Notch signaling pathway during the postnatal 
pituitary development. Other studies have alluded to a relationship between Notch 
signaling pathway and GRHL2. In the liver, Grhl2 and other Notch targets including 
Hes1, Hey1 and Sox9 are co-expressed in cholangiocytes and both Notch and GRHL2 
have been implicated in cholangiocyte differentiation (Tanimizu and Miyajima, 2004; 
Tanimizu et al., 2014; Wang et al., 2014). In addition, studies in the lung have 
demonstrated that GRHL2 can regulate expression of Notch receptors, indicating a 
reciprocal relationship between these factors (Gao et al., 2015). Taken together, these 
studies suggest that Notch regulation of GRHL2 may be a mechanism by which the 
pathway influences cellular dynamics in many tissues.  
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In other tissues, GRHL2 has been shown to directly regulate the expression of Cdh1 (E-
cad), a cellular adhesion molecule (Varma et al., 2012; Werth et al., 2010). We 
demonstrate that expression of this direct transcriptional target is also significantly 
reduced in Notch2 cKO. These studies suggest that GRHL2 may regulate cellular 
adhesion in the developing pituitary. In particular, E-cad expression is enriched in the 
pituitary progenitor population, and therefore GRHL2 may function to maintain the 
pituitary stem cell niche. This idea is also supported by the observation that GRHL2 
expression is increased in Ames dwarf pituitaries which display an inability of pituitary 
progenitors to differentiate, due in part to elevated expression of cellular adhesion 
molecules such as E-cad in the progenitor cell niche (Pérez Millán et al., 2016). The 
stem cell niche, a specialized microenvironment composed of extracellular matrix 
proteins, soluble factors and support cells, has been shown to be vitally important in 
maintaining stem cell function in other tissues. In the pituitary, very little is known about 
the components or regulators of the progenitor cell niche. Therefore, it critical to 
understand how Notch signaling and its downstream targets such as GRHL2 influence 
the progenitor cell niche components. Determining the factors that impact the progenitor 
microenvironment will also be particularly important in recapitulating developmental 
processes for in vitro therapeutic applications.   
Our studies suggest that Notch regulation of GRHL2 may be a potential mechanism by 
which this pathway influences progenitor cell function. Future studies are necessary to 
prove Grhl2 is a direct transcription target of the Notch signaling pathway. In addition, 
functional studies are necessary to definitively demonstrate the role of GRHL2 in 
progenitor cell function and to elucidate if GRHL2 has a functionally distinct role from 
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other pituitary stem cell factors such as SOX2 and SOX9. These functional studies may 
be challenging because there are no commercially available mice with floxed Grhl2 
alleles to generate conditional mutations. In addition, mice with global loss of Grhl2 or 
mice with ENU-induced nonsense mutation in the Grhl2 gene die during early 
embryogenesis due to neural tube defects (Pyrgaki et al., 2011; Rifat et al., 2010). 
Finally, studies suggest the grainyhead-like family members which also include GRHL1 
and GRHL3 have redundant or compensatory roles and therefore loss of GRHL2 alone 
may not display a phenotype. 
Notch signaling regulates expression of Hsd11b1, a pre-receptor regulator of 
glucocorticoid signaling, in the postnatal pituitary  
In addition to the role the Notch signaling pathway plays in progenitor cell maintenance 
this pathway also regulates the balance of endocrine cell differentiation during pituitary 
gland development. In multiple models of reduced Notch signaling, it has been shown 
that the pathway promotes the development of the PIT1 lineage cell types which 
includes somatotropes, lactotropes and thyrotropes, while opposing the differentiation of 
corticotrope lineage (Nantie et al., 2014; Zhu et al., 2006). In Chapter 4, we aimed to 
identify novel targets that contribute to Notch signaling regulation of corticotrope cell 
number.  We identified the gene 11-beta hydroxysteroid dehydrogenase type 1 
(Hsd11b1), a pre-receptor regulator of glucocorticoid action, as a Notch signaling target 
gene.  
In numerous tissues, 11β-HSD1 regulates the availability of active glucocorticoids, 
converting inactive forms of glucocorticoids (corticosterone and 11-
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dehydrocorticosterone) into their biologically active forms (cortisol and corticosterone).  
This is of interest in regard to corticotrope differentiation because in models of reduced 
glucocorticoid signaling such as adrenalectomy and conditional loss of glucocorticoid 
receptor (GR, gene name; Nr3c1), an apparent increase in corticotrope cell number is 
observed (Nolan et al., 2004; Schmidt et al., 2009). Therefore, in our study we propose 
Notch regulation of Hsd11b1 expression is a mechanism by which this signaling 
pathway functions to suppress aberrant corticotrope differentiation.   
Our study is the first to identify Hsd11b1 as a Notch signaling-dependent gene. We 
demonstrate Hsd11b1 is drastically reduced in mice treated with a chemical Notch 
signaling inhibitor and in Notch2 cKO mice. Interestingly, in Notch2 cKO pituitaries, 
Hsd11b1 expression is lost in both the pituitary progenitor cell compartment and in 
endocrine cells. The Notch signaling pathway is not thought to be active in endocrine 
cell types, therefore the observation that Hsd11b1 expression is lost in both cell 
populations may suggest Notch signaling influences transcriptional events required for 
the initial expression of Hsd11b1 in the developing pituitary. Our studies also strongly 
suggest Hsd11b1 is a direct transcriptional target of the Notch signaling pathway. In the 
regulatory regions of the Hsd11b1 gene, we identified several putative binding sites for 
the essential Notch signaling co-factor protein, RBPJ.  We demonstrate that one of the 
sites, which contains a putative RBPJ binding element conserved between species, is 
dynamically regulated in the presence of active Notch signaling suggesting that this site 
may be of importance for Notch regulation of Hsd11b1 in the developing pituitary.  
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It is important to note that in these studies, cellular context was a critical factor in 
demonstrating Notch regulation of Hsd11b1. We performed similar experiments in 
several cell lines but only observed Notch regulation in primary pituitary cells. The 
observation indicates the mechanism of Notch regulation of Hsd11b1 gene expression 
is likely cell-specific. Transcriptional regulation of Notch target genes is dependent on 
the formation of a co-activator complex which initiates in response to the notch 
intracellular domain (NICD) binding to RBPJ. This notch activation complex can 
subsequently recruit other co-activators proteins such as chromatin remodeling factors 
and histone acetyltransferases. The co-activator proteins required for transcription are 
gene dependent and therefore these factors can contribute to tissue-specific regulation 
of Notch target genes (Reviewed in (Borggrefe and Liefke, 2012)).  In addition, studies 
in both C. elegans and Drosophila have shown that Notch cooperates or physically 
interacts with cell-specific transcription factors to regulate transcription of downstream 
targets (Furriols et al., 2001; Neves et al., 2007; Oswald et al., 2001). Therefore, Notch 
regulation of Hsd11b1 expression may be dependent on a pituitary-specific Notch 
activation complex or pituitary-specific transcription factors. Furthermore, requirements 
for Notch regulation of Hsd11b1 could also be different in each pituitary cell type, as 
they all express a distinct network of transcription factors.  
A central aim of Chapter 4 was to understand the function of the 11β-HSD1 in the 
developing pituitary and relate this function to the changes in corticotrope cell number 
observed in Notch2 cKO mice. To address this aim, we used in vivo and in vitro models 
of reduced 11β-HSD1 activity. We demonstrate that pituitaries treated in vitro with a 
chemical 11β-HSD1 inhibitor have increases in corticotrope lineage genes including 
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Pomc and Tpit, a transcription factor the is required for corticotrope lineage 
specification. These initial studies suggest that 11β-HSD1 functions to suppress 
corticotrope gene expression and changes in Tpit gene expression are indicative of 
alternations in cell number. In addition, we generated mice with a conditional loss of 
Hsd11b1 in Pomc (Hsd11b1 cKO) expressing cells, which includes both corticotropes 
and melanotropes. This model was utilized to determine the function of 11β-HSD1 in 
corticotrope cells and to understand how the loss of Hsd11b1 expression in the 
corticotrope lineage could contribute to alterations in corticotrope differentiation. We 
determined that loss of Hsd11b1 results in increased expression of corticotrope specific 
genes which mimics gene expression changes observed in Notch2 cKO mice. However, 
unlike Notch2 cKO mice, we did not observe any difference in corticotrope cell number 
in Hsd11b1 cKO pituitaries during postnatal development. Our in vivo model indicates 
that 11β-HSD1 functions to suppress corticotrope gene expression but does not 
contribute to regulation of corticotrope cell number in this specific context.  
Our studies demonstrate that Hsd11b1 is a novel Notch signaling target gene that 
functions to suppress corticotrope gene expression. These studies are also the first to 
suggest that crosstalk between the Notch and glucocorticoid signaling pathways may 
have an important role in pituitary gland development. Our studies did not definitively 
prove Notch regulation of Hsd11b1 is a mechanism by which the pathway suppresses 
corticotrope differentiation. Our in vivo model of reduced Hsd11b1 expression in Pomc 
expressing cells did not alter corticotrope cell number. It is important to note that this 
model does not fully recapitulate the loss of Hsd11b1 is Notch2 cKO mice as these mice 
have reduced expression of Hsd11b1 in both POMC expressing cells and in pituitary 
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progenitors. Therefore, the ability of 11β-HSD1 to regulate corticotrope differentiation 
may occur in progenitor cells or transit amplifying cells prior to lineage commitment.  
Future studies utilizing a mouse model in which Hsd11b1 is conditionally lost in all 
pituitary cell types or specifically in progenitor cell population, will be necessary to fully 
elucidate the role of 11β-HSD1 in the regulation of corticotrope differentiation. These 
experiments may be hindered by the limited availability of genetic models with pituitary-
specific cre-mediated recombination drivers that are active in all cells early in 
development. Currently, the majority of mice models used to create conditional 
knockouts have cre-recombinase activity in extra-pituitary tissues. Therefore, 
interpretation of pituitary-specific effects may be difficult in an Hsd11b1 conditional 
knockout because glucocorticoid signaling is an important regulator of development 
processes in many tissues that may influence pituitary gland development or function. 
One promising model will be to use Prop1-cre mice to generate conditional knockouts of 
Hsd11b1. PROP1 is pituitary-specific transcription factor expressed in progenitor cells. 
Davis et al. demonstrate that cre-recombinase activity in Prop1-cre animals closely 
parallels endogenous Prop1 expression and is not detected outside of the pituitary 
(Davis et al., 2016). Therefore, this model may be useful in future studies to assess 
11β-HSD1 role in pituitary gland development.  
Overall Conclusions 
The works presented in Chapters 3 and 4 greatly expand our knowledge of the 
mechanism by which Notch signaling regulates pituitary progenitor cell maintenance 
and endocrine cell fate choice. Specifically, our studies demonstrate that the influence 
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of Notch signaling on pituitary cell fate is not solely dictated by transcriptional regulation 
of canonical downstream targets such as members of the Hes and Hey family. Rather, 
the Notch signaling pathway can regulate several novel targets that function in widely 
different capacities to influence pituitary gland development. Additionally, our work 
demonstrates the complexities of Notch signaling in the developing pituitary, as this 
pathway may function to modulate other molecular signaling pathways as a part of its 
regulatory mechanism. Dysregulation of the Notch signaling pathway has been 
associated with pituitary disease including pituitary adenomas and cases of 
hypopituitarism. Therefore, our studies will help in understanding how alterations in this 
pathway may contribute to changes in cell fate in pituitary disease states.  
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